BUKTI KORESPONDENSI
ARTIKEL JURNAL INTERNASIONAL BEREPUTASI

Judul Artikel : **Bioprospecting of bacterial symbionts of sponge Spongia officinalis from Savu Sea, Indonesiaf or antibacterial potential against multidrug-resistant bacteria**

Jurnal : BIODIVERSITAS, Volume 23, Number 2, Februari 2022, Pages: 1118-1124
ISSN: 1412-033X, E-ISSN: 2085-4722
DOI: 10.13057/biodiv/d230256

Penulis : Penulis pertama sekaligus koresponding

No	Perihal	Tanggal
1	Bukti konfirmasi submit artikel dan artikel yang disubmit	19 Januari 2022
2	Bukti konfirmasi review dan hasil review	20 Januari 2022
3	Bukti konfirmasi submit revisi dan artikel yang diresubmit	20 Januari 2022
4	Bukti konfirmasi review ke dua dan hasil review	21 Januari 2022
5	Bukti konfirmasi submit revisi ke dua dan artikel yang diresubmit	24 Januari 2022
6	Bukti konfirmasi artikel accepted	09 Februari 2022
7	Bukti konfirmasi artikel published online	09 Februari 2022

1 Bukti konfirmasi submit artikel dan artikel yang disubmit (19 Januari 2022)



COVERING LETTER

Dear **Editor-in-Chief,**

I herewith enclosed a research article,

Title:

Bioprospecting of Bacterial Symbionts of Sponge *Spongia officinalis* from Savu Sea, East Nusa Tenggara, Indonesia: Antibacterial potential against multidrug-resistant bacteria

Author(s) name:

MUHAMMAD EVY PRASTIYANTO[1♥] Aprilia Indra Kartika[2], Sri Darmawati[3], Ocky Karna Radjasa[4,5]

Address

(Fill in your institution's name and address, your personal cellular phone and email)

[1]Microbiology Laboratory, Department of Medical Laboratory Technology, Health and Nursing Faculty, Universitas Muhammadiyah Semarang, Jl. Kedungmundu Raya No. 18, Semarang, 50273, Indonesia. Phone: +62886618, Email: evy_prastiyanto@unimus.ac.id
[2]Molecular Biology Laboratory, Department of Medical Laboratory Technology, Health and Nursing Faculty, Universitas Muhammadiyah Semarang, Jl. Kedungmundu Raya No. 18, Semarang, 50273, Indonesia, Phone: +6285227496236, Email: apriliaindrak@gmail.com

[3]Magister Program of Medical Laboratory Science, Universitas Muhammadiyah Semarang, Jl. Kedungmundu Raya No. 18, Semarang, 50273, Indonesia, Phone: +628122503552, Email: ciciekdarma@unimus.ac.id
[4]Department of Marine Science, Faculty of Fisheries and Marine Science, Universitas Diponegoro. Jl. Prof. H. Soedarto, S.H., Tembalang, Semarang 50275, Central Java, Indonesia
[5] Indonesian Institute of Sciences, Gatot Subroto 10, Jakarta 12710, Indonesia

For possibility publication on the journal:

(fill in *Biodiversitas* or *Nusantara Bioscience* or *mention the others*)

Biodiversitas

Novelty:

(state your claimed novelty of the findings versus current knowledge)

Marine sponge *Spongia* sp. has been reported to have potential as an antibacterial agent. However, less information on the potential of bacterial symbionts of *Spongia sp.* as an antibacterial agent has been documented. To minimize this research gap, we focused this research on the bacterial isolates of *S. officinalis* which have antibacterial activity against multidrug resistance (MDR)-bacteria isolated from clinical specimens. These results provide information about the potential of bacterial symbionts of *S. officinalis* as natural antibacterial sources against MDR bacteria.

Statements:

This manuscript has not been published and is not under consideration for publication to any other journal or any other type of publication (including web hosting) either by me or any of my co-authors. Author(s) has been read and agree to the Ethical Guidelines.

List of five potential reviewers

(Fill in names of five potential reviewers **that agree to review your manuscpt** and their **email** addresses. He/she should have Scopus ID and come from different institution with the authors; and from at least three different countries)

1. Name: Tjahjadi Purwoko
Email: tjahjadipurwoko@yahoo.co.id, Institution: Universitas Sebelas Maret, URL Scopus: https://www.scopus.com/authid/detail.uri?authorId=57096077100

2. Name: Pitopang, Ramadanil
Email: pitopang_64@yahoo.com, Institution: Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Tadulako, URL Scopus: https://www.scopus.com/authid/detail.uri?authorId=8981197300

3. Name: Zubair, Muhammad Sulaiman

Institution: Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Tadulako, Url Scopus: https://www.scopus.com/authid/detail.uri?authorId=56723623400

4. Name: Myron L Smith
Institution: Department of Biology, Carleton University, 1125 Colonel By Drive, Ottawa, Ont., Canada K1S 5B6, Email: mysmith@ccs.carleton.ca,

5. Name: Christine E Ficker
Institution: Department of Biology, Carleton University, 1125 Colonel By Drive, Ottawa, Ont., Canada K1S 5B6

Place and date:

Semarang, 19-01-2022

Sincerely yours,

(fill in your name, no need scanned autograph)

Muhammad Evy Prastiyanto

Bioprospecting of Bacterial Symbionts of Sponge *Spongia officinalis* from Savu Sea, East Nusa Tenggara, Indonesia: Antibacterial potential against multidrug-resistant bacteria

Muhammad Evy Prastiyanto[1♥], Aprilia Indra Kartika[2], Sri Darmawati[3], Ocky Karna Radjasa[4,5]

[1]Microbiology Laboratory, Department of Medical Laboratory Technology, Health and Nursing Faculty, Universitas Muhammadiyah Semarang, Jl. Kedungmundu Raya No. 18, Semarang, 50273, Indonesia. Phone: +62886618, Email: evy_prastiyanto@unimus.ac.id

[2]Molecular Biology Laboratory, Department of Medical Laboratory Technology, Health and Nursing Faculty, Universitas Muhammadiyah Semarang, Jl. Kedungmundu Raya No. 18, Semarang, 50273, Indonesia, Phone: +6285227496236, Email: apriliaindrak@gmail.com

[3]Magister Program of Medical Laboratory Science, Universitas Muhammadiyah Semarang, Jl. Kedungmundu Raya No. 18, Semarang, 50273, Indonesia, Phone: +628122503552, Email: ciciekdarma@unimus.ac.id

[4]Department of Marine Science, Faculty of Fisheries and Marine Science, Universitas Diponegoro. Jl. Prof. H. Soedarto, S.H., Tembalang, Semarang 50275, Central Java, Indonesia

[5] Indonesian Institute of Sciences, Gatot Subroto 10, Jakarta 12710, Indonesia

Abstract

Marine sponge *Spongia* sp. has been reported to have potential as an antibacterial agent. However, less information on the potential of bacterial symbionts of *Spongia sp.* as an antibacterial agent has been documented. To minimize this research gap, we focused this research on the bacterial isolates of *S. officinalis* which have antibacterial activity against multidrug resistance (MDR)-bacteria isolated from clinical specimens. *S. officinalis* sp. was obtained from Savu Sea, East Nusa Tenggara, Indonesia and its symbionts were isolated with Zobell Marine Agar media. The overlay method was used to screen the antibacterial activity against six MDR bacteria. Antibacterial activity was determined by measuring the diameter of the inhibition zone. Identification of active bacterial symbionts was carried out based on the 16S rRNA gene sequence. The results revealed that four out of 10 symbionts showed antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL-*E. coli* and ESβL + CRE-*K. Pneumoniae* sp. *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate showed antibacterial activity against CRPA. The molecular identification of the active symbionts based on the 16S rRNA gene indicates that they belong to the *Bacillus* genus. These results provide information about the potential of bacterial symbionts of *S. officinalis* as natural antibacterial sources against MDR bacteria.

Keyword: Antibacterial, Multidrug-resistant, bacterial symbionts, sponge, *Spongia officinalis*.

Introduction

Infectious disease attributed to multidrug resistance (MDR) bacteria has become a health problem throughout the world including Indonesia. The use of antibiotics without following the guidelines is one of the causes of bacterial resistance to antibiotics (Bologa et al., 2013). Patients infected with MDR bacteria have a high risk due to difficult treatment and the need for more

sources of treatment compared to the patients suffering from infections that are not related to MDR (Word Health Organization, 2018). The Center for Diseases Control and Prevention (CDC) identifies the top MDR bacteria based on their threats. Several pathogenic bacteria such as methicillin-resistant, ESβL-producing *Enterobacteriaceae*, carbapenemase-resistant and Vancomycin-resistant are considered to be MDR bacteria that cause serious dangers (CDC, 2019).

Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common resistant bacterium and is the main cause of nosocomial infections worldwide, including in Indonesia. The prevalence rate of MRSA in hospitals in several Asian countries such as Korea, Japan, South, Taiwan, and China is 70–80% (Song et al., 2011). The carriage MRSA rate is 4.3% (64 of 1,502) among surgery patients at discharge from Indonesian hospitals (Mayer et al., 2010). Meanwhile, the resistance of *Enterococci* bacteria to the vancomycin group has also become a serious problem. The emergence of the vancomycin-resistant *Enterococci* (VRE)- *Enterococcus faecalis* strains has caused great difficulties in antibiotic therapy (Adhikari, 2010).

In Gram-negative, β-lactam is the most commonly used antibiotic to fight against infection, so many Gram-negative bacteria are resistant to β-lactam antibiotics. ESβL–producing *Enterobacteriaceae*, especially *Escherichia coli* and *Klebsiella pneumoniae* subsp *pneumoniae* have increased dramatically over the past few years (Kim et al., 2002). Nearly 30% of ESβL-producing *K. pneumoniae* were identified from the total positive cultures in clinical specimens of patients at a hospital in South Sulawesi, Indonesia (Waworuntu et al., 2021). The resistance of Gram-negative bacteria to the *Carbapenem* class antibiotics has entered the critical list (WHO, 2017) and a natural antibacterial agent is required to be taken from a biological source.

Natural anti-MDR bacterial agents can be obtained from fruits (Prastiyanto et al., 2020d), seeds (Prastiyanto et al., 2020a; Prastiyanto, 2021), Latex (Prastiyanto et al., 2020c) lactic acid bacteria (Lestari et al., 2019), mushroom (Prastiyanto et al., 2020b, 2016), and bacterial isolates from marine organisms (Al-dhabi et al., 2020), In recent years, there have been many studies on bioactive compounds from marine sources (Webster and Taylor, 2012). The bioactive potential of marine sources is effective in fighting pathogens that infect humans (Blunt et al., 2017), Marine organisms including sponges, corals, Cnidaria, Arthropods, Echinodermata, and Tunicates have attracted the attention of many scientists over the past few decades because of the bioactive compound contents (Nalini et al., 2018; Radjasa et al., 2013, 2011). Sponges are one of the most potential marine organisms that have the potential for bioactive compounds. The bioactive compounds have been used as the sources of drugs such as anti-tumor, anti-cancer, anti-inflammatory, cytotoxic, anti-malarial, antifouling, and immunosuppressive, antiviral, antifungal, and antibacterial (Mayer et al., 2010).

Sponge is a marine biota with secondary metabolite compounds potential as an antibacterial agent. Many studies have reported that sponges occupy the highest position of marine life, which shows potential as an antibacterial agent. A novel alkaloid isoaaptamine isolated from the sponge *Aaptos aaptos* inhibits sortase A (SrtA), an enzyme that plays a key role in the retention and virulence of cell wall proteins in *S. aureus* (Jang et al., 2007).Three polybrominated diphenyl ethers are produced from the *Dysidea* granulose (marine sponge). They possessed broad-spectrum activity against methicillin-sensitive *S. aureus* (MSSA) and MRSA

(Sun et al., 2015). However, obtaining bioactive compounds from marine sources requires a lot of materials. This will damage the marine ecosystem if the sponge is exploited continuously.

Spongia sp. has been reported to have bioactive compounds in the form of merosesquiterpenes, which show antibacterial activity against *S. aureus* (Nguyen et al., 2017). However, there is no information on the potential of bacterial symbionts of *Spongia sp.* as an antibacterial agent. Several studies have recounted that many bioactive compounds from marine life are similar to the bioactive compounds of microorganisms associated with these marine biotas (König et al., 2006). Therefore, to minimize the research gaps, this present study aimed at isolating bacteria associated with *Spongia officinalis* with the potential of anti-MDR activities from clinical samples.

Materials and Methods

The collection of sponge samples

Sponge samples were collected approximately from a depth of 1.5 m from Savu Sea, Kupang, East Nusa Tenggara, Indonesia in 8 November 2019 at 10°08'22.0"S 123°37'39.2"E (Fig. 1). The obtained samples were then put into sterile bags underwater, stored in a cooler (4°C), and brought to the laboratory. The identification and classification of sponges were carried out in the Diponegoro University Fisheries and Marine Laboratory.



Fig 1: Map of the study areas in the Savu Sea, Kupang, East Nusa Tenggara, Indonesia. A-D, Sampling sites and E, *S. officinalis* collected from the sampling site

Isolation of bacterial symbionts of S. officinalis

The sponge was processed under aseptic conditions. 1g of *S. officinalis* was rinsed with sterile seawater three times, crushed, and added with 9 mL of sterile seawater. The sponge sample was then diluted with 10^{-4}, 100 µL of which was taken and spread on Zobell Marine Agar (Marine Agar 2216) Himedia® media, and then incubated at 35 ± 2°C for one week. Colonies were

selected based on morphological differences. Colonies with different morphologies were transferred to the same media to obtain a pure culture.

Bacterial preparation

The MDR bacteria in this study are summarized in Table 1. MDR bacteria were isolated from patients of the hospital Dr. Kariadi, Semarang City, Indonesia. All isolates were identified and susceptibility patterns were obtained using Vitek®MS (bioM´erieux). The MDR bacteria were sub-cultured on 5% sheep blood agar (BAP) overnight (24 h) at 35±2ºC. The MDR bacteria colonies were homogenized and adjusted to 0.5 McFarland standards (5×10^8 CFU/mL) using McFarland Densitometer.

Table 1: The organisms for in vitro antibacterial screening in this study

No	Species	Source	Antibiotic resistance pattern
1	ESβL- *E. coli*	Urine	*Ampicillin, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ciprofloxacin, Nitrofurantoin Sulfamethoxazole*
2	ESβL + CR-*K. pneumoniae* subsp *pneumoniae*	Urine	*Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ertapenem, Meropenem, Ciprofloxacine, Sulfamethoxazole*
3	CRPA	sputum	*Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin Gentamicin, Ciprofloxacin, Tigecycline, Nitrofurantoin, Sulfamethoxazole*
4	MDRO-*Acinetobacter baumanii*	Urine	*Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin, Gentamicin, Ciprofloxacine, Sulfamethoxazole*
5	MRSA	Wound	*Benzylpenicillin, Oxacillin, Gentamicin, Ciprofloxacin, Levofloxacin, Moxifloxacin, Nitrofurantoin, Sulfamethoxazole*
6	VRE *Enterococcus faecalis*	Urine	*Gentamicin, Streptomycin, Ciprofloxacin, Levofloxacin, Erythromycin, Dalfopristin, Vancomycin, Tetracycline*

ESβL: extended-spectrum beta-lactamase, CR: Carbapenem-resistant, CRPA: Carbapenem-resistant *Pseudomonas aeruginosa*, MDRO: Multidrug-Resistant Organisms, MRSA: Methicillin-resistant *Staphylococcus aureus*, VRE: Vancomycin-resistant *Enterococci*

Screening for antibacterial activities against MDR bacteria

Screening to determine the antibacterial activity against MDR bacteria was carried out using the overlay method (Radjasa et al., 2013). The pure culture was inoculated ± 1 cm2 on Zobell Marine Agar medium in triplicate. After the bacteria grew, depending on the growth rate of the bacteria, which was commonly 1-7 days, the surface of the media was covered with Muller Hilton soft agar (0.3% (w/v) Muller Hilton Broth, 1% (w/v) NaCl and 0.7% (w/v) agar containing 1% (v/v) MDR bacteria (ESβL-*E. coli*, ESβL+CRE-*K. pneumoniae* subsp *pneumonia*e, CRPA, MRSA, and VRE-*E. faecalis*.

All the plates were then incubated aerobically at 35 ± 2°C for 24 hours. Antibacterial activity of the isolates was determined by measuring the diameter of the inhibition zone in mm

around the bacteria isolates. The levels of antibacterial activity were categorized as follows: no antibacterial activity (-), 0-1 mm (+), 1-3 mm (++), 3-7 mm (+++) and 7-15 mm (++++) (Asagabaldan et al., 2019). The inhibition area was measured to confirm the antibacterial activity (Apsari et al., 2019).

$$\text{Inhibition index (II)} = \frac{\text{Diameter inhibition area (mm)} - \text{diameter colony (mm)}}{\text{Diameter colony (mm)}}$$

Molecular identification of active bacterias symbionts of S. officinalis

DNA was extracted from bacterial cells (up to 1 x 10^9) using Presto^{TM} Mini g DNA Bacteria Kit (Geneaid) according to the appropriate protocols in the manufacturer's instructions, with a final elution volume of 50 µL. Extracted DNA was stored at 4°C until required for PCR. The concentration of bacterial DNA used was 50 ng/µL. The volume of bacterial DNA was 2 µL and mix with 16S rRNA primer. This step using 2 µL of 16S rRNA primer 27F '5'-AGAGTTGATCMTGGCTCAG-3' and 2 µL of 16S rRNA primer 1492R '5'-CGGTTACCTTGTTACGACTT-3'. The final concentration of 10 µM primer was 10 µM. Formulation mixing are Nuclease free water 6,5 µL, master mix (Promega) 12,5 µL, Primer and DNA template. The amplification conditions of both PCRs were as follows. The heat started to activate the Taq polymerase enzyme at a temperature of 95°C for 4 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, primer annealing at 57°C for 30 seconds, extension at 72°C for 2 minutes, an extra extension for 72°C at 10 minutes, and cooling down at 4°C for 10 minutes on a Biometra Thermal cycler. PCR products were separated on a 2% agarose gel and DNA bands were visualized with Flourovue. 4 µL of FluoroVue was added to a mixture of 1 g agarose and 100 ml TAE. PCR product sequencing was carried out by PT. Genetica Science Tangerang to analyze 16S rRNA sequences. Then the tracking results through the Basic Local Alignment Search Tool (BLAST) database program at the National Center for Biotechnology Information, National Institute for Health, USA (www.ncbi.nlm.nih.gov) were deposited to GenBank to obtain access numbers.

Phylogenetic analysis

MEGA X software was used for phylogenetic analysis. The results of DNA sequencing were aligned using ClustalW. The phylogenetic trees were determined by the neighbor-joining method with Tamura-Nei model and completed with Non-parametric bootstrapping analysis (1000 datasets) from 16S rRNA gene sequences showing the phylogenetic relationships of strains from this study to closely related species and some other selected strains.

Results

Bacterial symbionts of S. officinalis

The isolation of bacterial symbiont of *S. officinalis* resulted in 10 isolates, as presented in Fig. 2. The results of colony morphology and Gram staining characterization of bacterial isolates associated with *S. officinalis* are presented in Table 2. The outcomes showed different characters of bacteria isolates. The five of 10 isolates were rod-shaped, Gram-positive, and endospore-forming. Four isolates were rod-shaped, Gram-positive, non-endospore-forming, while one isolate showed Gram-negative Coccus.



Fig. 2. Pictures of macroscopic morphology of bacteria isolated from *S. officinalis* on Zobell Marine Agar (Marine Agar 2216) medium

Table 2. Morphology colony and Gram staining of bacteria isolated from *S. officinalis*

Isolate	Morphology colony			Gram staining
	Form	Margin	Elevation	
Prastiyanto-1A	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1B	Irregular	Undulate	Convex	Rod-shaped, Gram-negative, endospore-forming
Prastiyanto-1C	Circular	Entire	Convex	Coccus Gram-negative
Prastiyanto-1D	Irregular	Erose	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1E	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-2A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-3A	Irregular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4B	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4C	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Antibacterial activities against MDR bacteria

Antibacterial activity against MDR bacteria of bacterial of *S. officinalis* is indicated by the presence of an inhibition zone (Fig. 3). The inhibition zone is a qualitative way to determine the ability of an antimicrobial agent to inhibit the growth of microorganisms, particularly the MDR bacteria. The results of this study revealed that four (40%) of 10 isolates showed antibacterial activity against MDR bacteria. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL-*E. coli* and ESβL+CRE-*K. pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate proved antibacterial activity against CRPA.



Fig. 3. Zones of inhibition of bacteria isolated from *S. officinalis* against MDR bacteria: (a) ESβL- *E. coli*, (b) ESβL + CRE-*K. pneumoniae* subsp *pneumonia*, (c) MRSA, and (d) CRPA. → Zone of inhibition, → colony of bacteria isolated from *S. officinalis*

Identification of bacteria symbionts of S. officinalis

Identification of the active bacterial symbionts *S. officinalis* that showed antibacterial activity against MDR was performed based on the 16S rRNA gene (Fig. 4). The results showed that four isolates having antibacterial activity against MRD bacteria belonged to the members of the *Bacillus* genus.

Table 3. Antibacterial activities of bacteria isolated from *S. officinalis* against multidrug-resistant bacteria

Isolate	MDR bacteria											
	ESβL- *E. coli*		ESβL + CRE-*K. pneumoniae* subsp *pneumoniae*		CRPA		MDRO- *A. baumanii*		MRSA		VRE-*E. faecalis*	
	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)
Prastiyanto-1A	+++	6.4	++++	7.7	-	-	-	-	-	-	-	-
Prastiyanto-1B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1C	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1D	-	-	-	-	-	-	-	-	-	-	-	-

Prastiyanto-1E	+++	6.1	++++	9.2	-	-	-	-	-	-	-	-
Prastiyanto-2A	-	-	-	-	-	-	-	-	++++	12.6	-	-
Prastiyanto-3A	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4A	-	-	-	-	+++	4.8	-	-	-	-	-	-
Prastiyanto-4B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4C	-	-	-	-	-	-	-	-	-	-	-	-

Note: - denotes no effect

Phylogenetic analyses

Phylogenetic analysis showed that all strains related to the genera validly described species originating from marine habitats. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. *B. subtilis* SWI4a was a bacterium isolated from seaweed *Anthophycus longifolius* and has antibacterial activity.(Chakraborty et al., 2014)



Fig. 4. Phylogenetic affiliation of the active bacterial symbionts of *S. afficinalis*

Discussion

10 isolates produced by bacterial symbiont of *S. officinalis* (Table 2) and the results are in line with the findings of previous studies. Trianto et al. (2019) reported that 324 bacterial isolates associated with 55 sponges (isolates and Sponges ratio of 5.1-10.5) were produced. According to Webster and Thomas (2016), the diversity level of bacteria associated with sponges greatly varies among sponge species. Characterization of bacterial isolates associated with *S. officinalis* was carried out macroscopically (colony morphology) and microscopic (Gram staining).

The level of antibacterial activity of *S. officinalis* isolates against MDR bacteria is presented in Table 3. The results of this study proved that Prastiyanto-1A, Prastiyanto-1E, Pratiyanto-2A and Prastiyanto-4A isolates associated with *S. officinalis* indicated antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. These findings are consistent with the results of previous studies regarding the antibacterial activity of *S. officinalis* extract. *S. officinalis* extract with methanol-toluene solvent was able to inhibit the

growth of *S. epidermidis* (5-12 mm), *Streptococcus lactis* (5-12 mm), and *Bacillus subtilis* (2-5 mm) (McCaffrey and Endean, 1985).

Relevant studies reported that extracts of *S. officinalis* could inhibit *S. aureus* and *P. aeruginosa* (Gonaález et al., 1982). Moreover, it was also reported that microorganisms associated with marine biota are the producers of bioactive compounds (König et al., 2006). Davidson and Haygood (1999) confirmed that the producer of the bryostatin compound from *Bugula neritina* was the microbial symbionts of *Candidatus Endobugula sertula*.(Davidson and Haygood, 1999) The antibacterial activity against MDR bacteria belonged to the members of the *Bacillus* genus. Previous studies on bacteria associated with *Spongia* have shown similar results (Odekina et al., 2020). According to Mondol et al. (2013) *Bacillus* isolated from the sea produces secondary metabolites various antimicrobial activities (Mondol et al., 2013).

Phylogenetic analysis showed that Prastiyanto-1E isolate was closely related to *B. subtilis* PBBBS1, a bacterium isolated from the marine sediments of the Burmanallah coast (Cherian et al., 2019). Prastiyanto-4A isolate was very much linked to *B. mojavensis* ifo 15718, which was distilled from the sea and had antimicrobial potential (Ma et al., 2012) while Prastiyanto-2A isolate was associated with *B. simplex* K1-6 isolated from a coastal city, Izmir, Turkey.(Cherian et al., 2019) The bioactive compounds of all isolates that have the potential to act as anti-bacterial agents against MDR bacteria in this study have not been investigated. However, several studies have reported the antibacterial potential of the Bacillus genus members. *Surfactin* produced by *B. subtilis* C9 exhibits antibacterial and antiviral activities (Kim et al., 1997). MacrolactinW extracted from ethyl acetate fraction from the fermentation of *Bacillus sp.* 09ID194 isolated from the sea showed strong antibacterial activity against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Mondol et al., 2011).

Conclusion

In conclusion, the bacterial symbionts of *S. officinalis* potential as antibacterial agents against MDR bacteria belong to *Bacillus*. These results provide information about the potential of bacteria associated with *S. officinalis* as natural antibacterial sources against MDR bacteria.

Acknowledgments

The authors would like to thank Gaudensius U.U. Boli Duhan, M.Sc. from Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Katolik Widya Mandira, Kupang, Indonesia for help during sampling on Savu Sea, Kupang, East Nusa Tenggara, Indonesia

References

Adhikari L. 2010. High-level Aminoglycoside Resistance and Reduced Susceptibility to Vancomycin in Nosocomial *Enterococci*. J Clob Infect Dis 2, 231–235.

https://doi.org/10.4103/0974-777X.68534
Al-dhabi NA., Esmail GA., Ghilan AM, Arasu MV, Duraipandiyan V, Ponmurugan K. 2020. Chemical constituents of *Streptomyce*s sp. strain Al-Dhabi-97 isolated from the marine region of Saudi Arabia with antibacterial and anticancer properties. J. Infect. Public Health 13, 235–243.
Apsari PP, Budiarti SRI, Wahyudi ATRI. 2019. *Actinomycetes* of rhizosphere soil producing antibacterial compounds against Urinary Tract Infection bacteria. Biodiversitas 20, 1259–1265. https://doi.org/10.13057/biodiv/d200504
Asagabaldan MA, Bedoux G, Bourgougnon N. 2019. Bacterial isolates from bryozoan *Pleurocodonellina* sp .: Diversity and antimicrobial potential against pathogenic bacteria. Biodiversitas 20, 2528–2535. https://doi.org/10.13057/biodiv/d200914
Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR. 2017. Marine natural products. Nad prod Rep 34, 235–294. https://doi.org/10.1039/c4np00144c
Bologa CG, Ursu O, Oprea T. Melançon CE, Tegos G. 2013. Emerging Trends in the Discovery of Natural Product Antibacterials Cristian. Curr Opin Pharmacol. 13, 678–687. https://doi.org/10.1016/j.cortex.2009.08.003.Predictive
CDC. 2019. Biggest Threats and Data 2019 AR Threats Report [WWW Document]. Centers Diesease Control Prev.
Chakraborty K, Thilakan B, Raola VK. 2014. Polyketide family of novel antibacterial 7-O-methyl-5′-hydroxy-3′-heptenoate-macrolactin from seaweed-associated *Bacillus subtilis* MTCC 10403. J. Agric. Food Chem. https://doi.org/10.1021/jf504845m
Cherian T, Suneelkumar Y, Mohanraju R. 2019. Isolation of bacteria from marine sediments of Burmanallah coast, Port Blair. Ocean Stud. Mar. Biol.
Davidson SK, Haygood MG. 1999. Identification of sibling species of the bryozoan *Bugula neritina* that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "*Candidatus Endobugula sertula*". Biol Bull 196, 273–80. https://doi.org/10.2307/1542952
Gonaález AG, Darias V, Estévez E. 1982. Contribution to the biological study of *Spongia officinalis*. Farm. Sci 37, 179–83.
Jang KH, Chung SC, Shin J, Lee SH, Kim TI, Lee HS, Oh KB. 2007. Aaptamines as sortase A inhibitors from the tropical sponge *Aaptos aaptos*. Bioorganic Med. Chem. Lett. 17, 5366–5369. https://doi.org/10.1016/j.bmcl.2007.08.007
Kim HS, Yoon BD, Lee CH, Suh HH, Oh HM, Katsuragi T, Tani Y. 1997. Production and properties of a lipopeptide biosurfactant from *Bacillus subtilis* C9. J. Ferment. Bioeng. 84, 41–46. https://doi.org/10.1016/S0922-338X(97)82784-5
Kim Y, Pai H, Lee H, Park S, Choi E, Kim-Jungmin. 2002. Bloodstream Infections by Extended-Spectrum B-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* in Children : Epidemiology and Clinical Outcome. Antimicrob. Agent Chemotheray 46, 1481–1491. https://doi.org/10.1128/AAC.46.5.1481
König GM, Kehraus S, Seibert SF, Abdel-lateff A, Müller D. 2006. Natural products from marine organisms and their associated microbes. Chembiochem 7, 229–38. https://doi.org/10.1002/cbic.200500087
Lestari SD, Sadiq ALO, Safitri WA, Dewi SS, Prastiyanto ME. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. J. Phys. Conf. Ser. 1375, 012021. https://doi.org/10.1088/1742-6596/1374/1/012021

316 Ma Z, Wang N, Hu J, Wang S. 2012. Isolation and characterization of a new iturinic lipopeptide,
317 mojavensin A produced by a marine-derived bacterium *Bacillus mojavensis* B0621A. J.
318 Antibiot. (Tokyo). 65, 317–322. https://doi.org/10.1038/ja.2012.19
319 Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ,
320 Potts BC, Shuster DE. 2010. The odyssey of marine pharmaceuticals: a current pipeline
321 perspective. Trends Pharmacol. Sci. 31, 255–265. https://doi.org/10.1016/j.tips.2010.02.005
322 McCaffrey EJ, Endean R. 1985. Antimicrobial activity of tropical and subtropical sponges. Mar.
323 Biol. 89, 1–8.
324 Mondol MAM, Kim JH, Lee HS, Lee YJ, Shin HJ. 2011. Macrolactin W, a new antibacterial
325 macrolide from a marine *Bacillus* sp. Bioorganic Med. Chem. Lett. 21, 3832–3835.
326 https://doi.org/10.1016/j.bmcl.2010.12.050
327 Mondol MAM, Shin HJ, Islam MT. 2013. Diversity of secondary metabolites from marine
328 *Bacillus* species: Chemistry and biological activity. Mar. Drugs 11, 2846–2872.
329 https://doi.org/10.3390/md11082846
330 Nalini S, Richard DS, Riyaz SUM, Kavitha G, Inbakandan D. 2018. International Journal of
331 Biological Macromolecules Antibacterial macro molecules from marine organisms. Int. J.
332 Biol. Macromol. 115, 696–710. https://doi.org/10.1016/j.ijbiomac.2018.04.110
333 Nguyen MH, Ito T, Kurimoto S, Ogawa M, Nwet N, Quoc V, Thi H, Kubota T, Morita H. 2017.
334 Bioorganic & Medicinal Chemistry Letters New merosesquiterpenes from a Vietnamese
335 marine sponge of *Spongia* sp . and their biological activities. Bioorg. Med. Chem. Lett. 27,
336 3043–3047. https://doi.org/10.1016/j.bmcl.2017.05.060
337 Odekina PA, Agbo MO, Omeje EO. 2020. Antimicrobial and Antioxidant Activities of Novel
338 Marine Bacteria (*Bacillus* 2011SOCCUF3) Isolated from Marine Sponge (Spongia
339 officinalis). Pharm. Sci. 26, 82–87. https://doi.org/10.34172/PS.2019.59
340 Prastiyanto ME. 2021. Seeds extract of three Artocarpus species : Their in-vitro antibacterial
341 activities against multidrug-resistant (MDR) Escherichia coli isolates from urinary tract
342 infections (UTIs). Biodiversitas 22, 4356–4362. https://doi.org/10.13057/biodiv/d221028
343 Prastiyanto ME, Azizah IH, Haqi HD, Yulianto BD, Agmala AB, Radipasari ZD, Astuti NAD.
344 2020a. In-vitro antibacterial activity of the seed extract of three member Artocarpus towards
345 methicillin resistant *Staphylococcus aureus* (MRSA). J. Teknol. Lab. 9, 1–6.
346 https://doi.org/10.29238/tek
347 Prastiyanto ME, Rukmana RM, Saraswati DK, Darmawati S, Maharani ETW, Tursinawati Y,
348 2020b. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and
349 antibacterial activity against Methicillin-Resistant Staphylococcus aureus. Biodiversitas 21,
350 5644–5649. https://doi.org/10.13057/biodiv/d211221
351 Prastiyanto ME, Setyaningtyas A, Trisnawati L, Syafira A. 2016. Antimicrobial Activity and
352 Identification The Compounds of Methanol Extract from The *Pleurotus Ostreatus* Fruiting
353 Body. el-Hayah 6, 29–34.
354 Prastiyanto ME, Tama PD, Ananda N, Wilson W, Mukaromah AH. 2020c. Antibacterial Potential
355 of *Jatropha* sp. Latex against Multidrug-Resistant Bacteria. Int. J. Microbiol. 2020.
356 https://doi.org/https://doi.org/10.1155/2020/8509650
357 Prastiyanto ME, Wardoyo FA, Wilson W, Darmawati S. 2020d. Antibacterial Activity of Various
358 Extracts of *Averrhoa bilimbi* against Multidrug Resistant Bacteria. Biosaintifika 12, 163–
359 168.
360 Radjasa OK, Khoeri MM, Darusallam CC, Trimasanto H, Sudoyo H. 2013. Bacterial symbionts
361 of reef invertebrates: Screening for anti-pathogenic bacteria activity. Biodiversity 14, 80–

86. https://doi.org/10.1080/14888386.2013.774937
Radjasa OK, Vaske YM, Navarro G, Vervoort HC, Tenney K, Linington RG, Crews P. 2011. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg Med Chem. 19, 6658–6674. https://doi.org/10.1016/j.bmc.2011.07.017.Highlights
Song J, Hsueh P, Chung DR, Ko KS, Kang C, Peck KR. 2011. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries : An ANSORP study Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : an ANSORP. J Antimicrob Chemother 66, 1062–1069. https://doi.org/10.1093/jac/dkr024
Sun S, Canning CB, Bhargava K, Sun X, Zhu W, Zhou N, Zhang Y, Zhou K. 2015. Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge *Dysidea*. Bioorganic Med. Chem. Lett. 25, 2181–2183. https://doi.org/10.1016/j.bmcl.2015.03.057
Waworuntu O, Sjahril R, Rasita YD, Munawir M. 2021. Characteristic of extended-spectrum-B-lactamase (ESBL) Producing *Klebsiella pneumoniae* at tertiary referral hospital in South Sulawesi, Indonesia. Int. J. Infect. Dis. 101, 80. https://doi.org/10.1016/j.ijid.2020.09.236
Webster NS, Taylor MW. 2012. Marine sponges and their microbial symbionts : love. Environ. Microbiol. 14, 335–346. https://doi.org/10.1111/j.1462-2920.2011.02460.x
Word Health Organization. 2017. Essential medicines and health products Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. (accessed 4.9.21)
Word Health Organization. 2018. Resistance in bacteria Antibiotic. URL http://www.who.int/mediacentre/factsheets/fs194/en/ (accessed 4.9.21).

2 Bukti konfirmasi review dan hasil review 20 Januari 2022



Bioprospecting of bacterial symbionts of sponge *Spongia officinalis* from Savu Sea, East Nusa Tenggara, Indonesia: Antibacterial potential against multidrug-resistant bacteria

Commented [Ajar Nath1]:

Bioprospecting of bacterial symbionts of sponge Spongia officinalis from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

Abstract. Marine sponge *Spongia* sp. has been reported to have potential as an antibacterial agent. However, less information on the potential of bacterial symbionts of *Spongia* sp. as an antibacterial agent has been documented. To minimize this research gap, we focused this research on the bacterial isolates of *S. officinalis* which have antibacterial activity against multidrug resistance (MDR)-bacteria isolated from clinical specimens. *S. officinalis* was collected from Savu Sea, East Nusa Tenggara, Indonesia and its symbionts were isolated with Zobell marine agar media. The overlay method was used to screen the antibacterial activity against selected six MDR bacteria. Antibacterial activity was determined by measuring the diameter of the inhibition zone. Identification of active bacterial symbionts was carried out based on the 16S rRNA gene sequencing. The results revealed that four out of 10 symbionts showed antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *Escherichia coli* and ESβL + CRE- *Klebsiella pneumoniae* subsp *pneumoniae* , Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate showed antibacterial activity against CRPA. The molecular identification of the active symbionts based on the 16S rRNA gene indicates that they belong to the *Bacillus* genus. These results provide information about the potential of bacterial symbionts of *S. officinalis* as natural antibacterial sources against MDR bacteria.

Keyword: Antibacterial, Multidrug-resistant, bacterial symbionts, sponge, *Spongia officinalis*.

Commented [Ajar Nath2]: Reframe this sentences and donot use “We”

Commented [Ajar Nath3]: Give the details name here

INTRODUCTION

Infectious disease attributed to multidrug resistance (MDR) bacteria has become a health problem throughout the world including Indonesia. The use of antibiotics without following the guidelines is one of the causes of bacterial resistance to antibiotics (Bologa et al., 2013). Patients infected with MDR bacteria have a high risk due to difficult treatment and the need for more sources of treatment compared to the patients suffering from infections that are not related to MDR (Word Health Organization, 2018). The Center for Diseases Control and Prevention (CDC) identifies the top MDR bacteria based on their threats. Several pathogenic bacteria such as methicillin-resistant, ESβL-producing Enterobacteriaceae, carbapenemase-resistant and Vancomycin-resistant are considered to be MDR bacteria that cause serious dangers (CDC, 2019).

Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common resistant bacterium and is the main cause of nosocomial infections worldwide, including in Indonesia. The prevalence rate of MRSA in hospitals in several Asian countries such as Korea, Japan, South, Taiwan, and China is 70–80% (Song et al., 2011). The carriage MRSA rate is 4.3% (64 of 1,502) among surgery patients at discharge from Indonesian hospitals (Mayer et al., 2010). Meanwhile, the resistance of Enterococci bacteria to the vancomycin group has also become a serious problem. The emergence of the vancomycin-resistant *Enterococci* (VRE)- *Enterococcus faecalis* strains has caused great difficulties in antibiotic therapy (Adhikari, 2010).

In Gram-negative, β-lactam is the most commonly used antibiotic to fight against infection, so many Gram-negative bacteria are resistant to β-lactam antibiotics. ESβL–producing Enterobacteriaceae, especially *Escherichia coli* and *Klebsiella pneumoniae* subsp *pneumoniae* have increased dramatically over the past few years (Kim et al., 2002). Nearly 30% of ESβL-producing *K. pneumoniae* were identified from the total positive cultures in clinical specimens of patients at a hospital in South Sulawesi, Indonesia (Waworuntu et al., 2021). The resistance of Gram-negative bacteria to the Carbapenem class antibiotics has entered the critical list (WHO, 2017) and a natural antibacterial agent is required to be taken from a biological source.

Commented [Ajar Nath4]: Reframe for correctness

Natural anti-MDR bacterial agents can be obtained from fruits (Prastiyanto et al., 2020d), seeds (Prastiyanto et al., 2020a; Prastiyanto, 2021), Latex (Prastiyanto et al., 2020c) lactic acid bacteria (Lestari et al., 2019), mushroom (Prastiyanto et al., 2020b, 2016), and bacterial isolates from marine organisms (Al-dhabi et al., 2020), In recent years, there have been many studies on bioactive compounds from marine sources (Webster and Taylor, 2012). The bioactive potential of marine sources is effective in fighting pathogens that infect humans (Blunt et al., 2017), Marine organisms including sponges, corals, Cnidaria, Arthropods, Echinodermata, and Tunicates have attracted the attention of many scientists over the past few decades because of the bioactive compound contents (Nalini et al., 2018; Radjasa et al., 2013, 2011). Sponges are one of the most potential marine organisms that have the potential for bioactive compounds. The bioactive compounds have been used as the sources of drugs such as anti-tumor, anti-cancer, anti-inflammatory, cytotoxic, anti-malarial, antifouling, immunosuppressive, antiviral, antifungal, and antibacterial (Mayer et al., 2010).

Sponges are marine biota with secondary metabolite compounds potential as an antibacterial agents. Many studies have reported that sponges occupy the highest position of marine life, which shows potential as an antibacterial agents. A novel alkaloid isoaaptamine isolated from the sponge *Aaptos aaptos* inhibits sortase A (SrtA), an enzyme that plays a key role in the retention and virulence of cell wall proteins in *S. aureus* (Jang et al., 2007). Three polybrominated diphenyl ethers are produced from the *Dysidea* granulose (marine sponge). They possessed broad-spectrum activity against methicillin-sensitive *S. aureus* (MSSA) and MRSA (Sun et al., 2015). However, obtaining bioactive compounds from marine sources requires a lot of materials. This will damage the marine ecosystem if the sponge is exploited continuously.

Spongia sp. has been reported to have bioactive compounds in the form of merosesquiterpenes, which show antibacterial activity against *S. aureus* (Nguyen et al., 2017). However, there is no information on the potential of bacterial symbionts of *Spongia* sp. as an antibacterial agent. Several studies have recounted that many

Commented [Ajar Nath5]: Please check and confirmed

bioactive compounds from marine life are similar to the bioactive compounds of microorganisms associated with these marine biotas (König et al., 2006). The present investigation deals with isolation of bacterial symbionts of sponge *Spongia officinalis* and characterization antibacterial potential against multidrug-resistant bacteria.

Commented [Ajar Nath6]:

Bioprospecting of bacterial symbionts of sponge Spongia officinalis from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

MATERIALS AND METHODS

The collection of sponge samples

Sponge samples were collected approximately from a depth of 1.5 m from Savu Sea, Kupang, East Nusa Tenggara, Indonesia in 8 November 2019 at 10°08'22.0"S 123°37'39.2"E (Figure 1). The obtained samples were then put into sterile bags underwater, stored in a cooler (4°C), and brought to the laboratory. The identification and classification of sponges were carried out in the Diponegoro University Fisheries and Marine Laboratory.



Figure 1: Map of the study areas in the Savu Sea, Kupang, East Nusa Tenggara, Indonesia. A-D, Sampling sites and E, *S. officinalis* collected from the sampling site

Isolation of bacterial symbionts of *Spongiaofficinalis*

The sponge was processed under aseptic conditions. One gram of *S. officinalis* was rinsed with sterile seawater three times, crushed, and added with 9 mL of sterile seawater. The sponge sample was then diluted with 10^{-4}, 100 µL of which was taken and spread on Zobell marine agar (Marine agar 2216) Himedia® media, and then incubated at 35 ± 2°C for one week. Colonies were selected based on morphological differences. Colonies with different morphologies were transferred to the same media to obtain a pure culture.

Bacterial preparation

MDR bacteria were isolated from patients of the hospital Dr. Kariadi, Semarang City, Indonesia (Table 1). All isolates were identified and susceptibility patterns were obtained using Vitek®MS (bioM´erieux). The MDR bacteria were sub-cultured on 5% sheep blood agar (BAP) overnight (24 h) at 35±2°C. The MDR bacterial colonies were homogenized and adjusted to 0.5 McFarland standards (5×10^8 CFU/mL) using McFarland Densitometer.

Commented [Ajar Nath7]: ????

Table 1: The organisms for *in vitro* antibacterial screening

No	Species	Source	Antibiotic resistance pattern
1	ESβL- *E. coli*	Urine	Ampicillin, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ciprofloxacin, Nitrofurantoin Sulfamethoxazole
2	ESβL + CR- *K. pneumoniae* subsp *pneumoniae*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ertapenem, Meropenem, Ciprofloxacine, Sulfamethoxazole
3	CRPA	Sputum	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin Gentamicin, Ciprofloxacin, Tigecycline, Nitrofurantoin, Sulfamethoxazole
4	MDRO-*Acinetobacter baumanii*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin, Gentamicin, Ciprofloxacine, Sulfamethoxazole
5	MRSA	Wound	Benzylpenicillin, Oxacillin, Gentamicin, Ciprofloxacin, Levofloxacin, Moxifloxacin, Nitrofurantoin, Sulfamethoxazole
6	VRE *Enterococcus faecalis*	Urine	Gentamicin, Streptomycin, Ciprofloxacin, Levofloxacin, Erythromycin, Dalfopristin, Vancomycin, Tetracycline

Note: ESβL: extended-spectrum beta-lactamase, CR: Carbapenem-resistant, CRPA: Carbapenem-resistant Pseudomonas aeruginosa, MDRO: Multidrug-Resistant Organisms, MRSA: Methicillin-resistant Staphylococcus aureus, VRE: Vancomycin-resistant Enterococci

Screening for antibacterial activities against MDR bacteria

Screening to determine the antibacterial activity against MDR bacteria was carried out using the overlay method (Radjasa et al., 2013). The pure culture was inoculated ± 1 cm2 on Zobell marine agar medium in triplicate. After the bacteria grew, depending on the growth rate of the bacteria, which was commonly 1-7 days, the surface of the media was covered with Muller Hilton soft agar (0.3% (w/v) Muller Hilton broth, 1% (w/v) NaCl and 0.7% (w/v) agar containing 1% (v/v) MDR bacteria (ESβL- *E. coli*, ESβL+CRE- *K. pneumoniae* subsp *pneumonia*e, CRPA, MRSA, and VRE- *E. faecalis*.

All the plates were then incubated aerobically at 35 ± 2°C for 24 hours. Antibacterial activity of the isolates were determined by measuring the diameter of the inhibition zone in mm around the bacterial isolates. The levels of antibacterial activity were categorized as follows: no antibacterial activity (-), 0-1 mm (+), 1-3 mm (++), 3-7 mm (+++) and 7-15 mm (++++) (Asagabaldan et al., 2019). The inhibition area was measured to confirm the antibacterial activity (Apsari et al., 2019).

$$\text{Inhibition index (II)} = \frac{\text{Diameter inhibition area (mm)} - \text{diameter colony (mm)}}{\text{Diameter colony (mm)}}$$

Molecular identification of active bacterial symbionts of *S. officinalis*

DNA was extracted from bacterial cells (up to 1 x 10^9) using Presto™ Mini g DNA Bacteria Kit (Geneaid) according to the appropriate protocols in the manufacturer's instructions, with a final elution volume of 50 µL. Extracted DNA was stored at 4°C until required for PCR. The concentration of bacterial DNA used was 50 ng/µL. The volume of bacterial DNA was 2 µL and mix with 16S rRNA gene primer. This step using 2 µL of 16S rRNA gene primer 27F '5'-AGAGTTGATCMTGGCTCAG-3' and 2 µL of 16S rRNA gene primer 1492R '5'-CGGTTACCTTGTTACGACTT-3'. The final concentration of 10 µM primer was 10 µM. Formulation mixing are nuclease free water 6,5 µL, master mix (Promega) 12,5 µL, primer and DNA template. The amplification conditions of both PCRs were as follows. The heat started to activate the Taq polymerase enzyme at a temperature of 95°C for 4 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, primer annealing at 57°C for 30 seconds, extension at 72°C for 2 minutes, an extra extension for 72°C at 10 minutes, and cooling down at 4°C for 10 minutes on a Biometra Thermal cycler. PCR products were separated on a 2% agarose gel and DNA bands were visualized with Flourovue. Four microlitter of FluoroVue was added to a mixture of 1 g agarose and 100 ml TAE. PCR product sequencing was carried out by PT. Genetica Science

Commented [Ajar Nath8]: Do not start the sentence with numerical

Commented [Ajar Nath9]: ????

Tangerang to analyze 16S rRNA gene sequences, then the tracking results through the Basic Local Alignment Search Tool (BLAST) database program at the National Center for Biotechnology Information NCBI), National Institute for Health, USA (www.ncbi.nlm.nih.gov) were deposited to GenBank to obtain accession numbers.

Phylogenetic analysis

MEGA X software was used for phylogenetic analysis. The results of 16S rRNA gene sequencing were aligned using ClustalW. The phylogenetic trees were determined by the neighbor-joining method with Tamura-Nei model and completed with Non-parametric bootstrapping analysis (1000 datasets) from 16S rRNA gene sequences showing the phylogenetic relationships of closely related strains database available at NCBI GenBank..

RESULTS AND DISCUSSION

Bacterial symbionts of *Spongiaofficinalis*

The isolation of bacterial symbiont of *S. officinalis* resulted in 10 isolates, as presented in Figure 2. The results of colony morphology and Gram staining characterization of bacterial isolates associated with *S. officinalis* are presented in Table 2. The outcomes showed different characters of bacterial isolates. The five out of 10 isolates were rod-shaped, Gram-positive, and endospore-forming. Four isolates were rod-shaped, Gram-positive, non-endospore-forming, while one isolate showed Gram-negative coccus.

Commented [Ajar Nath10]: Reframe sentence

Commented [Ajar Nath11]: Don't write like this.

The table and figure should be at the end of end of sentence in bracket …..



Figure 2. Macroscopic morphology of bacteria isolated from *S. officinalis* on Zobell marine agar

Table 2. Morphology and Gram staining of bacteria isolated from *S. officinalis*

Isolate	Morphology colony			Gram staining
	Form	Margin	Elevation	
Prastiyanto-1A	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1B	Irregular	Undulate	Convex	Rod-shaped, Gram-negative, endospore-forming
Prastiyanto-1C	Circular	Entire	Convex	Coccus Gram-negative
Prastiyanto-1D	Irregular	Erose	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1E	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-2A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-3A	Irregular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Prastiyanto-4B	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4C	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Antibacterial activities against MDR bacteria

Antibacterial activity against MDR bacteria of bacterial of *S. officinalis* is indicated by the presence of an inhibition zone (Figure 3). The inhibition zone is a qualitative way to determine the ability of an antimicrobial agent to inhibit the growth of microorganisms, particularly the MDR bacteria. The results of this study revealed that four (40%) of 10 isolates showed antibacterial activity against MDR bacteria. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *E. coli* and ESβL+CRE- *K. pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate proved antibacterial activity against CRPA.



Figure 3. Zones of inhibition of bacteria isolated from *S. officinalis* against MDR bacteria: (a) ESβL- *E. coli*, (b) ESβL + CRE-*K. pneumoniae* subsp *pneumonia*, (c) MRSA, and (d) CRPA. → Zone of inhibition, → colony of bacteria isolated from *S. officinalis*

Identification of bacteria symbionts of *S. officinalis*

Identification of the active bacterial symbionts *S. officinalis* that showed antibacterial activity against MDR was performed based on the 16S rRNA gene (Figure 4). The results showed that four isolates having antibacterial activity against MRD bacteria belonged to the members of the *Bacillus* genus.

Commented [Ajar Nath12]: Give the complete name of bacteria with strain number

Table 3. Antibacterial activities of bacteria isolated from *S. officinalis* against multidrug-resistant bacteria

Isolate	MDR bacteria											
	ESβL- *E. coli*		ESβL + CRE-*K. pneumoniae* subsp *pneumoniae*		CRPA		MDRO- *A. baumanii*		MRSA		VRE-*E. faecalis*	
	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)
Prastiyanto-1A	+++	6.4	++++	7.7	-	-	-	-	-	-	-	-
Prastiyanto-1B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1C	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1D	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1E	+++	6.1	++++	9.2	-	-	-	-	-	-	-	-
Prastiyanto-2A	-	-	-	-	-	-	-	-	++++	12.6	-	-
Prastiyanto-3A	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4A	-	-	-	-	+++	4.8	-	-	-	-	-	-

Prastiyanto-4B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4C	-	-	-	-	-	-	-	-	-	-	-	-

Note: - denotes no effect

Phylogenetic analyses

Phylogenetic analysis showed that all strains related to the genera validly described species originating from marine habitats. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. *B. subtilis* SWI4a was a bacterium isolated from seaweed *Anthophycus longifolius* and has antibacterial activity.(Chakraborty et al., 2014)



Figure 4. Phylogenetic affiliation of the active bacterial symbionts of *S. afficinalis*

Discussion

Ten isolates produced by bacterial symbiont of *S. officinalis* (Table 2) and the results are in line with the findings of previous studies. Trianto et al. (2019) reported that 324 bacterial isolates associated with 55 sponges (isolates and Sponges ratio of 5.1-10.5) were produced. According to Webster and Thomas (2016), the diversity level of bacteria associated with sponges greatly varies among sponge species. Characterization of bacterial isolates associated with *S. officinalis* was carried out macroscopically (colony morphology) and microscopic (Gram staining).

The level of antibacterial activity of *S. officinalis* isolates against MDR bacteria is presented in Table 3. The results of this study proved that Prastiyanto-1A, Prastiyanto-1E, Pratiyanto-2A and Prastiyanto-4A isolates associated with *S. officinalis* indicated antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. These findings are consistent with the results of previous studies regarding the antibacterial activity of *S. officinalis* extract. *S. officinalis* extract with methanol-toluene solvent was able to inhibit the growth of *S. epidermidis* (5-12 mm), *Streptococcus lactis* (5-12 mm), and *Bacillus subtilis* (2-5 mm) (McCaffrey and Endean, 1985).

Relevant studies reported that extracts of *S. officinalis* could inhibit *S. aureus* and *P. aeruginosa* (Gonaález et al., 1982). Moreover, it was also reported that microorganisms associated with marine biota are the producers of bioactive compounds (König et al., 2006). Davidson and Haygood (1999) confirmed that the producer of the bryostatin compound from *Bugula neritina* was the microbial symbionts of *Candidatus Endobugula sertula*.(Davidson and Haygood, 1999) The antibacterial activity against MDR bacteria belonged to the members of the *Bacillus* genus. Previous studies on bacteria associated with *Spongia* have shown similar results (Odekina et al., 2020). According to Mondol et al. (2013) *Bacillus* isolated from the sea produces secondary metabolites various antimicrobial activities (Mondol et al., 2013).

Phylogenetic analysis showed that Prastiyanto-1E isolate was closely related to *B. subtilis* PBBBS1, a bacterium isolated from the marine sediments of the Burmanallah coast (Cherian et al., 2019). Prastiyanto-4A isolate was

Commented [Ajar Nath13]: Do not write "*S. afficinalis" in tree*

Give the strain number ONLY and with closely related identified bacteria

Commented [Ajar Nath14]: Revise the discussion section

Add some relevant recent references up to 2021

Commented [Ajar Nath15]: Reframe

Commented [Ajar Nath16]: Reframe

very much linked to *B. mojavensis* ifo 15718, which was distilled from the sea and had antimicrobial potential (Ma et al., 2012) while Prastiyanto-2A isolate was associated with *B. simplex* K1-6 isolated from a coastal city, Izmir, Turkey.(Cherian et al., 2019) The bioactive compounds of all isolates that have the potential to act as anti-bacterial agents against MDR bacteria in this study have not been investigated. However, several studies have reported the antibacterial potential of the *Bacillus* genus members. *Surfactin* produced by *B. subtilis* C9 exhibits antibacterial and antiviral activities (Kim et al., 1997). MacrolactinW extracted from ethyl acetate fraction from the fermentation of *Bacillus* sp. 09ID194 isolated from the sea showed strong antibacterial activity against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Mondol et al., 2011).

In conclusion, the bacterial symbionts of *S. officinalis* potential as antibacterial agents against MDR bacteria belong to *Bacillus*. These results provide information about the potential of bacteria associated with *S. officinalis* as natural antibacterial sources against MDR bacteria.

ACKNOWLEDGMENTS

The authors would like to thank Gaudensius U.U. Boli Duhan, M.Sc. from Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Katolik Widya Mandira, Kupang, Indonesia for help during sampling on Savu Sea, Kupang, East Nusa Tenggara, Indonesia

REFERENCES

Adhikari L. 2010. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial *Enterococci*. J. Clob. Infect. Dis. 2, 231–235. https://doi.org/10.4103/0974-777X.68534

Al-dhabi NA., Esmail GA., Ghilan AM, Arasu MV, Duraipandiyan V, Ponmurugan K. 2020. Chemical constituents of *Streptomyce*s sp. strain Al-Dhabi-97 isolated from the marine region of Saudi Arabia with antibacterial and anticancer properties. J. Infect. Public Health 13, 235–243.

Apsari PP, Budiarti SRI, Wahyudi ATRI. 2019. *Actinomycetes* of rhizosphere soil producing antibacterial compounds against Urinary Tract Infection bacteria. Biodiversitas 20, 1259–1265. https://doi.org/10.13057/biodiv/d200504

Asagabaldan MA, Bedoux G, Bourgougnon N. 2019. Bacterial isolates from bryozoan *Pleurocodonellina* sp .: Diversity and antimicrobial potential against pathogenic bacteria. Biodiversitas 20, 2528–2535. https://doi.org/10.13057/biodiv/d200914

Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR. 2017. Marine natural products. Nad prod Rep 34, 235–294. https://doi.org/10.1039/c4np00144c

Bologa CG, Ursu O, Oprea T. Melançon CE, Tegos G. 2013. Emerging trends in the discovery of natural product antibacterials cristian. Curr. Opin. Pharmacol. 13, 678–687. https://doi.org/10.1016/j.cortex.2009.08.003.Predictive

CDC. 2019. Biggest Threats and Data 2019 AR Threats Report [WWW Document]. Centers Diesease Control Prev.

Chakraborty K, Thilakan B, Raola VK. 2014. Polyketide family of novel antibacterial 7-O-methyl-5′-hydroxy-3′-heptenoate-macrolactin from seaweed-associated *Bacillus subtilis* MTCC 10403. J. Agric. Food Chem. https://doi.org/10.1021/jf504845m

Cherian T, Suneelkumar Y, Mohanraju R. 2019. Isolation of bacteria from marine sediments of Burmanallah coast, Port Blair. Ocean Stud. Mar. Biol.

Davidson SK, Haygood MG. 1999. Identification of sibling species of the bryozoan *Bugula neritina* that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "*Candidatus Endobugula sertula*". Biol Bull 196, 273–80. https://doi.org/10.2307/1542952

Gonaález AG, Darias V, Estévez E. 1982. Contribution to the biological study of *Spongia officinalis*. Farm. Sci 37, 179–83.

Jang KH, Chung SC, Shin J, Lee SH, Kim TI, Lee HS, Oh KB. 2007. Aaptamines as sortase A inhibitors from the tropical sponge *Aaptos aaptos*. Bioorganic Med. Chem. Lett. 17, 5366–5369. https://doi.org/10.1016/j.bmcl.2007.08.007

Kim HS, Yoon BD, Lee CH, Suh HH, Oh HM, Katsuragi T, Tani Y. 1997. Production and properties of a lipopeptide biosurfactant from *Bacillus subtilis* C9. J. Ferment. Bioeng. 84, 41–46. https://doi.org/10.1016/S0922-338X(97)82784-5

Kim Y, Pai H, Lee H, Park S, Choi E, Kim-Jungmin. 2002. Bloodstream Infections by Extended-Spectrum B-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* in Children : Epidemiology and Clinical Outcome. Antimicrob. Agent Chemotheray 46, 1481–1491. https://doi.org/10.1128/AAC.46.5.1481

König GM, Kehraus S, Seibert SF, Abdel-lateff A, Müller D. 2006. Natural products from marine organisms and their associated microbes. Chembiochem 7, 229–38. https://doi.org/10.1002/cbic.200500087

Lestari SD, Sadiq ALO, Safitri WA, Dewi SS, Prastiyanto ME. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. J. Phys. Conf. Ser. 1375, 012021. https://doi.org/10.1088/1742-6596/1374/1/012021

Ma Z, Wang N, Hu J, Wang S. 2012. Isolation and characterization of a new iturinic lipopeptide, mojavensin A produced by a marine-derived bacterium *Bacillus mojavensis* B0621A. J. Antibiot. (Tokyo). 65, 317–322. https://doi.org/10.1038/ja.2012.19

Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. 2010. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31, 255–265. https://doi.org/10.1016/j.tips.2010.02.005

McCaffrey EJ, Endean R. 1985. Antimicrobial activity of tropical and subtropical sponges. Mar. Biol. 89, 1–8.

Mondol MAM, Kim JH, Lee HS, Lee YJ, Shin HJ. 2011. Macrolactin W, a new antibacterial macrolide from a marine *Bacillus* sp. Bioorganic Med. Chem. Lett. 21, 3832–3835. https://doi.org/10.1016/j.bmcl.2010.12.050

Mondol MAM, Shin HJ, Islam MT. 2013. Diversity of secondary metabolites from marine *Bacillus* species: Chemistry and biological activity. Mar. Drugs 11, 2846–2872. https://doi.org/10.3390/md11082846

Nalini S, Richard DS, Riyaz SUM, Kavitha G, Inbakandan D. 2018. Antibacterial macro molecules from marine organisms. Int. J. Biol. Macromol. 115, 696–710. https://doi.org/10.1016/j.ijbiomac.2018.04.110

Nguyen MH, Ito T, Kurimoto S, Ogawa M, Nwet N, Quoc V, Thi H, Kubota T, Morita H. 2017. New merosesquiterpenes from a Vietnamese marine sponge of *Spongia* sp . and their biological activities. Bioorg. Med. Chem. Lett. 27, 3043–3047. https://doi.org/10.1016/j.bmcl.2017.05.060

Odekina PA, Agbo MO, Omeje EO. 2020. Antimicrobial and Antioxidant Activities of Novel Marine Bacteria (*Bacillus* 2011SOCCUF3) Isolated from Marine Sponge (*Spongia officinalis*). Pharm. Sci. 26, 82–87. https://doi.org/10.34172/PS.2019.59

Prastiyanto ME. 2021. Seeds extract of three *Artocarpus* species : Their in-vitro antibacterial activities against multidrug-resistant (MDR) *Escherichia coli* isolates from urinary tract infections (UTIs). Biodiversitas 22, 4356–4362. https://doi.org/10.13057/biodiv/d221028

Prastiyanto ME, Azizah IH, Haqi HD, Yulianto BD, Agmala AB, Radipasari ZD, Astuti NAD. 2020a. In-vitro antibacterial activity of the seed extract of three member *Artocarpus* towards methicillin resistant *Staphylococcus aureus* (MRSA). J. Teknol. Lab. 9, 1–6. https://doi.org/10.29238/tek

Prastiyanto ME, Rukmana RM, Saraswati DK, Darmawati S, Maharani ETW, Tursinawati Y, 2020b. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and antibacterial activity against Methicillin-Resistant *Staphylococcus aureus*. Biodiversitas 21, 5644–5649. https://doi.org/10.13057/biodiv/d211221

Prastiyanto ME, Setyaningtyas A, Trisnawati L, Syafira A. 2016. Antimicrobial Activity and Identification The Compounds of Methanol Extract from The *Pleurotus Ostreatus* Fruiting Body. el-Hayah 6, 29–34.

Prastiyanto ME, Tama PD, Ananda N, Wilson W, Mukaromah AH. 2020c. Antibacterial Potential of *Jatropha* sp. Latex against Multidrug-Resistant Bacteria. Int. J. Microbiol. 2020. https://doi.org/https://doi.org/10.1155/2020/8509650

Prastiyanto ME, Wardoyo FA, Wilson W, Darmawati S. 2020d. Antibacterial Activity of Various Extracts of *Averrhoa bilimbi* against Multidrug Resistant Bacteria. Biosaintifika 12, 163–168.

Radjasa OK, Khoeri MM, Darusallam CC, Trimasanto H, Sudoyo H. 2013. Bacterial symbionts of reef invertebrates: Screening for anti-pathogenic bacteria activity. Biodiversity 14, 80–86. https://doi.org/10.1080/14888386.2013.774937

Radjasa OK, Vaske YM, Navarro G, Vervoort HC, Tenney K, Linington RG, Crews P. 2011. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg Med Chem. 19, 6658–6674. https://doi.org/10.1016/j.bmc.2011.07.017.Highlights

Song J, Hsueh P, Chung DR, Ko KS, Kang C, Peck KR. 2011. Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : An ANSORP study Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : an ANSORP. J Antimicrob Chemother 66, 1062–1069. https://doi.org/10.1093/jac/dkr024

Sun S, Canning CB, Bhargava K, Sun X, Zhu W, Zhou N, Zhang Y, Zhou K. 2015. Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge *Dysidea*. Bioorganic Med. Chem. Lett. 25, 2181–2183. https://doi.org/10.1016/j.bmcl.2015.03.057

Waworuntu O, Sjahril R, Rasita YD, Munawir M. 2021. Characteristic of extended-spectrum-B-lactamase (ESBL) Producing *Klebsiella pneumoniae* at tertiary referral hospital in South Sulawesi, Indonesia. Int. J. Infect. Dis. 101, 80. https://doi.org/10.1016/j.ijid.2020.09.236

Webster NS, Taylor MW. 2012. Marine sponges and their microbial symbionts : love. Environ. Microbiol. 14, 335–346. https://doi.org/10.1111/j.1462-2920.2011.02460.x

Word Health Organization. 2017. Essential medicines and health products Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. (accessed 4.9.21)

Word Health Organization. 2018. Resistance in bacteria Antibiotic. URL http://www.who.int/mediacentre/factsheets/fs194/en/ (accessed 4.9.21).

3 Bukti konfirmasi submit revisi dan artikel yang diresubmit (20 Januari 2022)



Bioprospecting of bacterial symbionts of sponge *Spongia officinalis* from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

Commented [Ajar Nath17]:

Bioprospecting of bacterial symbionts of sponge Spongia officinalis from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

Abstract. Marine sponge *Spongia* sp. has been reported to have potential as an antibacterial agent. However, less information on the potential of bacterial symbionts of *Spongia* sp. as an antibacterial agent has been documented. To minimize this research gap, focused this research on the bacterial isolates of *S. officinalis* which have antibacterial activity against multidrug resistance (MDR)-bacteria isolated from clinical specimens. *S. officinalis* was collected from Savu Sea, East Nusa Tenggara, Indonesia and its symbionts were isolated with Zobell marine agar media. The overlay method was used to screen the antibacterial activity against selectedsix MDR bacteria. Antibacterial activity was determined by measuring the diameter of the inhibition zone. Identification of active bacterial symbionts was carried out based on the 16S rRNA gene sequencing. The results revealed that four out of 10 symbionts showed antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *Escherichia coli* and ESβL + CRE- *Klebsiella pneumoniae* subsp *pneumoniae* , Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate showed antibacterial activity against CRPA. The molecular identification of the active symbionts based on the 16S rRNA gene indicates that they belong to the *Bacillus subtilis, B. mojavenensis* and *B. simplex* These results provide information about the potential of bacterial symbionts of *S. officinalis* as natural antibacterial sources against MDR bacteria.

Keyword: Antibacterial, Multidrug-resistant, bacterial symbionts, sponge, *Spongia officinalis*.

INTRODUCTION

Infectious disease attributed to multidrug resistance (MDR) bacteria has become a health problem throughout the world including Indonesia. The use of antibiotics without following the guidelines is one of the causes of bacterial resistance to antibiotics (Bologa et al., 2013). Patients infected with MDR bacteria have a high risk due to difficult treatment and the need for more sources of treatment compared to the patients suffering from infections that are not related to MDR (Word Health Organization, 2018). The Center for Diseases Control and Prevention (CDC) identifies the top MDR bacteria based on their threats. Several pathogenic bacteria such as methicillin-resistant, ESβL-producing Enterobacteriaceae, carbapenemase-resistant and Vancomycin-resistant are considered to be MDR bacteria that cause serious dangers (CDC, 2019).

Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common resistant bacterium and is the main cause of nosocomial infections worldwide, including in Indonesia. The prevalence rate of MRSA in hospitals in several Asian countries such as Korea, Japan, South, Taiwan, and China is 70–80% (Song et al., 2011). The carriage MRSA rate is 4.3% (64 of 1,502) among surgery patients at discharge from Indonesian hospitals (Mayer et al., 2010). Meanwhile, the resistance of Enterococci bacteria to the vancomycin group has also become a serious problem. The emergence of the vancomycin-resistant *Enterococci* (VRE)- *Enterococcus faecalis* strains has caused great difficulties in antibiotic therapy (Adhikari, 2010).

β-lactam is the most commonly used antibiotic to fight against infection caused Gram-Negative bacteria, so many Gram-negative bacteria are resistant to β-lactam antibiotics. ESβL–producing Enterobacteriaceae, especially *Escherichia coli* and *Klebsiella pneumoniae* subsp *pneumoniae* have increased dramatically over the past few years (Kim et al., 2002). Nearly 30% of ESβL-producing *K. pneumoniae* were identified from the total positive cultures in clinical specimens of patients at a hospital in South Sulawesi, Indonesia (Waworuntu et al., 2021). The resistance of Gram-negative bacteria to the Carbapenem class antibiotics has entered the critical list (WHO, 2017) and a natural antibacterial agent is required to be taken from a biological source.

Commented [Ajar Nath18]: Reframe for correctness

Natural anti-MDR bacterial agents can be obtained from fruits (Prastiyanto et al., 2020d), seeds (Prastiyanto et al., 2020a; Prastiyanto, 2021), Latex (Prastiyanto et al., 2020c) lactic acid bacteria (Lestari et al., 2019), mushroom (Prastiyanto et al., 2020b, 2016), and bacterial isolates from marine organisms (Al-dhabi et al., 2020), In recent years, there have been many studies on bioactive compounds from marine sources (Webster and Taylor, 2012). The bioactive potential of marine sources is effective in fighting pathogens that infect humans (Blunt et al., 2017), Marine organisms including sponges, corals, Cnidaria, Arthropods, Echinodermata, and Tunicates have attracted the attention of many scientists over the past few decades because of the bioactive compound contents (Nalini et al., 2018; Radjasa et al., 2013, 2011). Sponges are one of the most potential marine organisms that have the potential for bioactive compounds. The bioactive compounds have been used as the sources of drugs such as anti-tumor, anti-cancer, anti-inflammatory, cytotoxic, anti-malarial, antifouling, immunosuppressive, antiviral, antifungal, and antibacterial (Mayer et al., 2010).

Sponges are marine biota with secondary metabolite compounds potential as an antibacterial agents. Many studies have reported that sponges occupy the highest position of marine life, which shows potential as an antibacterial agents. A novel alkaloid isoaaptamine isolated from the sponge *Aaptos aaptos* inhibits sortase A (SrtA), an enzyme that plays a key role in the retention and virulence of cell wall proteins in *S. aureus* (Jang et al., 2007). Three polybrominated diphenyl ethers are produced from the *Dysidea* granulose (marine sponge). They possessed broad-spectrum activity against methicillin-sensitive *S. aureus* (MSSA) and MRSA (Sun et al., 2015). However, obtaining bioactive compounds from marine sources requires a lot of materials. This will damage the marine ecosystem if the sponge is exploited continuously.

Spongia sp. has been reported to have bioactive compounds in the form of merosesquiterpenes, which show antibacterial activity against *S. aureus* (Nguyen et al., 2017). Several studies have recounted that many bioactive compounds from marine life are similar to the bioactive compounds of microorganisms associated with these marine biotas (König et al., 2006). The present investigation deals with isolation of bacterial symbionts of sponge *Spongia officinalis* and characterization antibacterial potential against multidrug-resistant bacteria.

Commented [Ajar Nath19]:

Bioprospecting of bacterial symbionts of sponge Spongia officinalis from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

MATERIALS AND METHODS

The collection of sponge samples

Sponge samples were collected approximately from a depth of 1.5 m from Savu Sea, Kupang, East Nusa Tenggara, Indonesia in 8 November 2019 at 10°08'22.0"S 123°37'39.2"E (Figure 1). The obtained samples were then put into sterile bags underwater, stored in a cooler (4°C), and brought to the laboratory. The identification and classification of sponges were carried out in the Diponegoro University Fisheries and Marine Laboratory.



Figure 1: Map of the study areas in the Savu Sea, Kupang, East Nusa Tenggara, Indonesia. A-D, Sampling sites and E, *S. officinalis* collected from the sampling site

Isolation of bacterial symbionts of *Spongiaofficinalis*

The sponge was processed under aseptic conditions. One gram of *S. officinalis* was rinsed with sterile seawater three times, crushed, and added with 9 mL of sterile seawater. The sponge sample was then diluted with 10^{-4}, 100 µL of which was taken and spread on Zobell marine agar (Marine agar 2216) Himedia® media, and then incubated at 35 ± 2°C for one week. Colonies were selected based on morphological differences. Colonies with different morphologies were transferred to the same media to obtain a pure culture.

Bacterial preparation

MDR bacteria were isolated from patients of the hospital Dr. Kariadi, Semarang City, Indonesia (Table 1). All isolates were identified and susceptibility patterns were obtained using Vitek®MS (bioM´erieux). The MDR bacteria were sub-cultured on 5% sheep blood agar plate (BAP) overnight (24 h) at 35±2°C. The MDR bacterial

Commented [Ajar Nath20]: ????

colonies were homogenized and adjusted to 0.5 McFarland standards (5×10^8 CFU/mL) using McFarland Densitometer.

Table 1: The organisms for *in vitro* antibacterial screening

No	Species	Source	Antibiotic resistance pattern
1	*ESβL- E. coli*	Urine	Ampicillin, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ciprofloxacin, Nitrofurantoin Sulfamethoxazole
2	*ESβL + CR- K. pneumoniae subsp pneumoniae*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ertapenem, Meropenem, Ciprofloxacine, Sulfamethoxazole
3	CRPA	Sputum	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin Gentamicin, Ciprofloxacin, Tigecycline, Nitrofurantoin, Sulfamethoxazole
4	*MDRO-Acinetobacter baumanii*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin, Gentamicin, Ciprofloxacine, Sulfamethoxazole
5	MRSA	Wound	Benzylpenicillin, Oxacillin, Gentamicin, Ciprofloxacin, Levofloxacin, Moxifloxacin, Nitrofurantoin, Sulfamethoxazole
6	*VRE Enterococcus faecalis*	Urine	Gentamicin, Streptomycin, Ciprofloxacin, Levofloxacin, Erythromycin, Dalfopristin, Vancomycin, Tetracycline

Note: ESβL: extended-spectrum beta-lactamase, CR: Carbapenem-resistant, CRPA: Carbapenem-resistant Pseudomonas aeruginosa, MDRO: Multidrug-Resistant Organisms, MRSA: Methicillin-resistant Staphylococcus aureus, VRE: Vancomycin-resistant Enterococci

Screening for antibacterial activities against MDR bacteria

Screening to determine the antibacterial activity against MDR bacteria was carried out using the overlay method (Radjasa et al., 2013). The pure culture was inoculated ± 1 cm2 on Zobell marine agar medium in triplicate. After the bacteria grew, depending on the growth rate of the bacteria, which was commonly 1-7 days, the surface of the media was covered with Muller Hilton soft agar (0.3% (w/v) Muller Hilton broth, 1% (w/v) NaCl and 0.7% (w/v) agar containing 1% (v/v) MDR bacteria (ESβL- *E. coli*, ESβL+CRE- *K. pneumoniae* subsp *pneumonia*e, CRPA, MRSA, and VRE- *E. faecalis*.

All the plates were then incubated aerobically at 35 ± 2°C for 24 hours. Antibacterial activity of the isolates were determined by measuring the diameter of the inhibition zone in mm around the bacterial isolates. The levels of antibacterial activity were categorized as follows: no antibacterial activity (-), 0-1 mm (+), 1-3 mm (++), 3-7 mm (+++) and 7-15 mm (++++) (Asagabaldan et al., 2019). The inhibition area was measured to confirm the antibacterial activity (Apsari et al., 2019).

$$\text{Inhibition index (II)} = \frac{\text{Diameter inhibition area (mm)} - \text{diameter colony (mm)}}{\text{Diameter colony (mm)}}$$

Molecular identification of active bacterial symbionts of *S. officinalis*

DNA was extracted from bacterial cells (up to 1×10^9) using Presto™ Mini g DNA Bacteria Kit (Geneaid) according to the appropriate protocols in the manufacturer's instructions, with a final elution volume of 50 µL. Extracted DNA was stored at 4°C until required for PCR. The concentration of bacterial DNA used was 50 ng/µL. The volume of bacterial DNA was 2 µL and mix with 16S rRNA gene primer. This step using 2 µL of 16S rRNA gene primer 27F '5'-AGAGTTGATCMTGGCTCAG-3' and 2 µL of 16S rRNA gene primer 1492R '5'-CGGTTACCTTGTTACGACTT-3'. The final concentration of 10 µM primer was 10 µM. Formulation mixing are nuclease free water 6,5 µL, master mix (Promega) 12,5 µL, primer and DNA template. The amplification conditions of both PCRs were as follows. The heat started to activate the Taq polymerase enzyme at a temperature of 95°C for 4 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, primer annealing at 57°C for 30 seconds, extension at 72°C for 2 minutes, an extra extension for 72°C at 10 minutes, and cooling down at 4°C for 10 minutes on a Biometra Thermal cycler. PCR products were separated on a 2%

agarose gel and DNA bands were visualized with Flourovue. Four microlitter of FluoroVue was added to a mixture of 1 g agarose and 100 ml TAE. PCR product sequencing was carried out by Genetica Science Tangerang to analyze 16S rRNA gene sequences, then the tracking results through the Basic Local Alignment Search Tool (BLAST) database program at the National Center for Biotechnology Information NCBI), National Institute for Health, USA (www.ncbi.nlm.nih.gov) were deposited to GenBank to obtain accession numbers.

Commented [Ajar Nath21]: Do not start the sentence with numerical

Phylogenetic analysis

MEGA X software was used for phylogenetic analysis. The results of 16S rRNA gene sequencing were aligned using ClustalW. The phylogenetic trees were determined by the neighbor-joining method with Tamura-Nei model and completed with Non-parametric bootstrapping analysis (1000 datasets) from 16S rRNA gene sequences showing the phylogenetic relationships of closely related strains database available at NCBI GenBank..

RESULTS AND DISCUSSION

Bacterial symbionts of *Spongiaofficinalis*

The isolation of bacterial symbiont of *S. officinalis* resulted in 10 isolates (Figure 2).. The outcomes showed different characters of bacterial isolates. The five out of 10 isolates were rod-shaped, Gram-positive, and endospore-forming. Four isolates were rod-shaped, Gram-positive, non-endospore-forming, while one isolate showed Gram-negative coccus (Table 2).

Commented [Ajar Nath22]: Reframe sentence



Figure 2. Macroscopic morphology of bacteria isolated from *S. officinalis* on Zobell marine agar

Table 2. Morphology and Gram staining of bacteria isolated from *S. officinalis*

Isolate	Morphology colony			Gram staining
	Form	Margin	Elevation	
Prastiyanto-1A	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1B	Irregular	Undulate	Convex	Rod-shaped, Gram-negative, endospore-forming
Prastiyanto-1C	Circular	Entire	Convex	Coccus Gram-negative
Prastiyanto-1D	Irregular	Erose	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1E	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-2A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-3A	Irregular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Prastiyanto-4A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4B	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4C	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Antibacterial activities against MDR bacteria

Antibacterial activity against MDR bacteria of bacterial of *S. officinalis* is indicated by the presence of an inhibition zone (Figure 3). The inhibition zone is a qualitative way to determine the ability of an antimicrobial agent to inhibit the growth of microorganisms, particularly the MDR bacteria. The results of this study revealed that four (40%) of 10 isolates showed antibacterial activity against MDR bacteria. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *E. coli* and ESβL+CRE- *K. pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate proved antibacterial activity against CRPA.



Figure 3. Zones of inhibition of bacteria isolated from *S. officinalis* against MDR bacteria: (a) ESβL- *E. coli*, (b) ESβL + CRE-*K. pneumoniae* subsp *pneumonia*, (c) MRSA, and (d) CRPA. → Zone of inhibition, → colony of bacteria isolated from *S. officinalis*

Identification of bacteria symbionts of *S. officinalis*

Identification of the active bacterial symbionts *S. officinalis* that showed antibacterial activity against MDR was performed based on the 16S rRNA gene (Figure 4). The results showed that four isolates having antibacterial activity against MRD bacteria belonged to the members of the *Bacillus* genus. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. Prastiyanto-1E isolate with *B. subtilis* PBBBS1, Prastiyanto-4A isolate with *B. mojavensis* ifo 15718 and Prastiyanto-2A isolate was closely related to *B. simplex* K1-6

Commented [Ajar Nath23]: Give the complete name of bacteria with strain number

Table 3. Antibacterial activities of bacteria isolated from *S. officinalis* against multidrug-resistant bacteria

Isolate	MDR bacteria											
	ESβL- *E. coli*		ESβL + CRE-*K. pneumoniae* subsp *pneumoniae*		CRPA		MDRO- *A. baumanii*		MRSA		VRE-*E. faecalis*	
	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)
Prastiyanto-1A	+++	6.4	++++	7.7	-	-	-	-	-	-	-	-
Prastiyanto-1B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1C	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1D	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1E	+++	6.1	++++	9.2	-	-	-	-	-	-	-	-
Prastiyanto-2A	-	-	-	-	-	-	-	-	++++	12.6	-	-

Prastiyanto-3A	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4A	-	-	-	-	+++	4.8	-	-	-	-	-	-
Prastiyanto-4B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4C	-	-	-	-	-	-	-	-	-	-	-	-

Note: - denotes no effect

Phylogenetic analyses

Phylogenetic analysis showed that all strains related to the genera validly described species originating from marine habitats. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. *B. subtilis* SWI4a was a bacterium isolated from seaweed *Anthophycus longifolius* and has antibacterial activity (Chakraborty et al., 2014).



Figure 4. Neighbor-joining tree constructed with Tamura-Nei model from 16S rRNA gene sequences showing the phylogenetic relationships of strains from this study to closely related species

The total of 10 strains was selected for isolation of pure cultures according to morphology colony and Gram staining (Table 2). Forty percent (4 isolates) of the total isolates showed inhibitory activities against MDR bacteria (Table 3).the results are in line with the findings of previous studies. Trianto et al. (2019) reported that 324 bacterial isolates associated with 55 sponges (isolates and Sponges ratio of 5.1-10.5) were produced. According to Webster and Thomas (2016), the diversity level of bacteria associated with sponges greatly varies among sponge species. Characterization of bacterial isolates associated with *S. officinalis* was carried out macroscopically (colony morphology) and microscopic (Gram staining).

Commented [Ajar Nath24]: Reframe

The results of this study proved that Prastiyanto-1A, Prastiyanto-1E, Pratiyanto-2A and Prastiyanto-4A isolates associated with *S. officinalis* indicated antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. These findings are consistent with the results of previous studies regarding the antibacterial activity of *S. officinalis* extract. *S. officinalis* extract with methanol-toluene solvent was able to inhibit the growth of *S. epidermidis* (5-12 mm), *Streptococcus lactis* (5-12 mm), and *Bacillus subtilis* (2-5 mm) (McCaffrey and Endean, 1985).

Relevant studies reported that extracts of *S. officinalis* could inhibit *S. aureus* and *P. aeruginosa* (Gonaález et al., 1982). Moreover, it was also reported that microorganisms associated with marine biota are the producers of bioactive compounds (König et al., 2006). Davidson and Haygood (1999) confirmed that the producer of the bryostatin compound from *Bugula neritina* was the microbial symbionts of *Candidatus Endobugula sertula*. The antibacterial activity against MDR bacteria belonged to the members of the *Bacillus* genus. Previous studies on bacteria associated with *Spongia* have shown similar results (Odekina et al., 2020). According to Mondol et al. (2013) *Bacillus* isolated from the sea produces secondary metabolites various antimicrobial activities (Mondol et al., 2013).

Phylogenetic analysis showed that Prastiyanto-1E isolate *B. subtilis* PBBBS1, a bacterium isolated from the marine sediments of the Burmanallah coast (Cherian et al., 2019). Prastiyanto-4A isolate was very much linked to *B. mojavensis* ifo 15718, which was distilled from the sea and had antimicrobial potential (Ma et al., 2012) while Prastiyanto-2A isolate was associated with *B. simplex* K1-6 isolated from a coastal city, Izmir, Turkey.(Cherian et al., 2019) The bioactive compounds of all isolates that have the potential to act as anti-bacterial agents against MDR bacteria in this study have not been investigated. However, several studies have reported the antibacterial potential of the *Bacillus* genus members. *Surfactin* produced by *B. subtilis* C9 exhibits antibacterial and antiviral activities (Kim et al., 1997). MacrolactinW extracted from ethyl acetate fraction from the fermentation of *Bacillus* sp. 09ID194 isolated from the sea showed strong antibacterial activity against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Mondol et al., 2011).

In conclusion, the bacterial symbionts of *S. officinalis* potential as antibacterial agents against MDR bacteria belong to *Bacillus*. These results provide information about the potential of bacteria associated with *S. officinalis* as natural antibacterial sources against MDR bacteria.

ACKNOWLEDGMENTS

The authors would like to thank Gaudensius U.U. Boli Duhan, M.Sc. from Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Katolik Widya Mandira, Kupang, Indonesia for help during sampling on Savu Sea, Kupang, East Nusa Tenggara, Indonesia

REFERENCES

Adhikari L. 2010. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial *Enterococci*. J. Clob. Infect. Dis. 2, 231–235. https://doi.org/10.4103/0974-777X.68534

Al-dhabi NA., Esmail GA., Ghilan AM, Arasu MV, Duraipandiyan V, Ponmurugan K. 2020. Chemical constituents of *Streptomyce*s sp. strain Al-Dhabi-97 isolated from the marine region of Saudi Arabia with antibacterial and anticancer properties. J. Infect. Public Health 13, 235–243.

Apsari PP, Budiarti SRI, Wahyudi ATRI. 2019. *Actinomycetes* of rhizosphere soil producing antibacterial compounds against Urinary Tract Infection bacteria. Biodiversitas 20, 1259–1265. https://doi.org/10.13057/biodiv/d200504

Asagabaldan MA, Bedoux G, Bourgougnon N. 2019. Bacterial isolates from bryozoan *Pleurocodonellina* sp .: Diversity and antimicrobial potential against pathogenic bacteria. Biodiversitas 20, 2528–2535. https://doi.org/10.13057/biodiv/d200914

Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR. 2017. Marine natural products. Nad prod Rep 34, 235–294. https://doi.org/10.1039/c4np00144c

Bologa CG, Ursu O, Oprea T. Melançon CE, Tegos G. 2013. Emerging trends in the discovery of natural product antibacterials cristian. Curr. Opin. Pharmacol. 13, 678–687. https://doi.org/10.1016/j.cortex.2009.08.003.Predictive

CDC. 2019. Biggest Threats and Data 2019 AR Threats Report [WWW Document]. Centers Diesease Control Prev.

Chakraborty K, Thilakan B, Raola VK. 2014. Polyketide family of novel antibacterial 7-O-methyl-5′-hydroxy-3′-heptenoate-macrolactin from seaweed-associated *Bacillus subtilis* MTCC 10403. J. Agric. Food Chem. https://doi.org/10.1021/jf504845m

Cherian T, Suneelkumar Y, Mohanraju R. 2019. Isolation of bacteria from marine sediments of Burmanallah coast, Port Blair. Ocean Stud. Mar. Biol.

Davidson SK, Haygood MG. 1999. Identification of sibling species of the bryozoan *Bugula neritina* that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "*Candidatus Endobugula sertula*". Biol Bull 196, 273–80. https://doi.org/10.2307/1542952

Gonaález AG, Darias V, Estévez E. 1982. Contribution to the biological study of *Spongia officinalis*. Farm. Sci 37, 179–83.

Jang KH, Chung SC, Shin J, Lee SH, Kim TI, Lee HS, Oh KB. 2007. Aaptamines as sortase A inhibitors from the tropical sponge *Aaptos aaptos*. Bioorganic Med. Chem. Lett. 17, 5366–5369. https://doi.org/10.1016/j.bmcl.2007.08.007

Kim HS, Yoon BD, Lee CH, Suh HH, Oh HM, Katsuragi T, Tani Y. 1997. Production and properties of a lipopeptide biosurfactant from *Bacillus subtilis* C9. J. Ferment. Bioeng. 84, 41–46. https://doi.org/10.1016/S0922-338X(97)82784-5

Kim Y, Pai H, Lee H, Park S, Choi E, Kim-Jungmin. 2002. Bloodstream Infections by Extended-Spectrum B-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* in Children : Epidemiology and Clinical Outcome. Antimicrob. Agent Chemotheray 46, 1481–1491. https://doi.org/10.1128/AAC.46.5.1481

König GM, Kehraus S, Seibert SF, Abdel-lateff A, Müller D. 2006. Natural products from marine organisms and their associated microbes. Chembiochem 7, 229–38. https://doi.org/10.1002/cbic.200500087

Lestari SD, Sadiq ALO, Safitri WA, Dewi SS, Prastiyanto ME. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. J. Phys. Conf. Ser. 1375, 012021. https://doi.org/10.1088/1742-6596/1374/1/012021

Ma Z, Wang N, Hu J, Wang S. 2012. Isolation and characterization of a new iturinic lipopeptide, mojavensin A produced by a marine-derived bacterium *Bacillus mojavensis* B0621A. J. Antibiot. (Tokyo). 65, 317–322. https://doi.org/10.1038/ja.2012.19

Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. 2010. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31, 255–265. https://doi.org/10.1016/j.tips.2010.02.005

McCaffrey EJ, Endean R. 1985. Antimicrobial activity of tropical and subtropical sponges. Mar. Biol. 89, 1–8.

Mondol MAM, Kim JH, Lee HS, Lee YJ, Shin HJ. 2011. Macrolactin W, a new antibacterial macrolide from a marine *Bacillus* sp. Bioorganic Med. Chem. Lett. 21, 3832–3835. https://doi.org/10.1016/j.bmcl.2010.12.050

Mondol MAM, Shin HJ, Islam MT. 2013. Diversity of secondary metabolites from marine *Bacillus* species: Chemistry and biological activity. Mar. Drugs 11, 2846–2872. https://doi.org/10.3390/md11082846

Nalini S, Richard DS, Riyaz SUM, Kavitha G, Inbakandan D. 2018. Antibacterial macro molecules from marine organisms. Int. J. Biol. Macromol. 115, 696–710. https://doi.org/10.1016/j.ijbiomac.2018.04.110

Nguyen MH, Ito T, Kurimoto S, Ogawa M, Nwet N, Quoc V, Thi H, Kubota T, Morita H. 2017. New merosesquiterpenes from a Vietnamese marine sponge of *Spongia* sp . and their biological activities. Bioorg. Med. Chem. Lett. 27, 3043–3047. https://doi.org/10.1016/j.bmcl.2017.05.060

Odekina PA, Agbo MO, Omeje EO. 2020. Antimicrobial and Antioxidant Activities of Novel Marine Bacteria (*Bacillus* 2011SOCCUF3) Isolated from Marine Sponge (*Spongia officinalis*). Pharm. Sci. 26, 82–87. https://doi.org/10.34172/PS.2019.59

Prastiyanto ME. 2021. Seeds extract of three *Artocarpus* species : Their in-vitro antibacterial activities against multidrug-resistant (MDR) *Escherichia coli* isolates from urinary tract infections (UTIs). Biodiversitas 22, 4356–4362. https://doi.org/10.13057/biodiv/d221028

Prastiyanto ME, Azizah IH, Haqi HD, Yulianto BD, Agmala AB, Radipasari ZD, Astuti NAD. 2020a. In-vitro antibacterial activity of the seed extract of three member *Artocarpus* towards methicillin resistant *Staphylococcus aureus* (MRSA). J. Teknol. Lab. 9, 1–6. https://doi.org/10.29238/tek

Prastiyanto ME, Rukmana RM, Saraswati DK, Darmawati S, Maharani ETW, Tursinawati Y, 2020b. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and antibacterial activity against Methicillin-Resistant *Staphylococcus aureus*. Biodiversitas 21, 5644–5649. https://doi.org/10.13057/biodiv/d211221

Prastiyanto ME, Setyaningtyas A, Trisnawati L, Syafira A. 2016. Antimicrobial Activity and Identification The Compounds of Methanol Extract from The *Pleurotus Ostreatus* Fruiting Body. el-Hayah 6, 29–34.

Prastiyanto ME, Tama PD, Ananda N, Wilson W, Mukaromah AH. 2020c. Antibacterial Potential of *Jatropha* sp. Latex against Multidrug-Resistant Bacteria. Int. J. Microbiol. 2020. https://doi.org/https://doi.org/10.1155/2020/8509650

Prastiyanto ME, Wardoyo FA, Wilson W, Darmawati S. 2020d. Antibacterial Activity of Various Extracts of *Averrhoa bilimbi* against Multidrug Resistant Bacteria. Biosaintifika 12, 163–168.

Radjasa OK, Khoeri MM, Darusallam CC, Trimasanto H, Sudoyo H. 2013. Bacterial symbionts of reef invertebrates: Screening for anti-pathogenic bacteria activity. Biodiversity 14, 80–86. https://doi.org/10.1080/14888386.2013.774937

Radjasa OK, Vaske YM, Navarro G, Vervoort HC, Tenney K, Linington RG, Crews P. 2011. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg Med Chem. 19, 6658–6674. https://doi.org/10.1016/j.bmc.2011.07.017.Highlights

Song J, Hsueh P, Chung DR, Ko KS, Kang C, Peck KR. 2011. Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : An ANSORP study Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : an ANSORP. J Antimicrob Chemother 66, 1062–1069. https://doi.org/10.1093/jac/dkr024

Sun S, Canning CB, Bhargava K, Sun X, Zhu W, Zhou N, Zhang Y, Zhou K. 2015. Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge *Dysidea*. Bioorganic Med. Chem. Lett. 25, 2181–2183. https://doi.org/10.1016/j.bmcl.2015.03.057

Waworuntu O, Sjahril R, Rasita YD, Munawir M. 2021. Characteristic of extended-spectrum-B-lactamase (ESBL) Producing *Klebsiella pneumoniae* at tertiary referral hospital in South Sulawesi, Indonesia. Int. J. Infect. Dis. 101, 80. https://doi.org/10.1016/j.ijid.2020.09.236

Webster NS, Taylor MW. 2012. Marine sponges and their microbial symbionts : love. Environ. Microbiol. 14, 335–346. https://doi.org/10.1111/j.1462-2920.2011.02460.x

Word Health Organization. 2017. Essential medicines and health products Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. (accessed 4.9.21)
Word Health Organization. 2018. Resistance in bacteria Antibiotic. URL http://www.who.int/mediacentre/factsheets/fs194/en/ (accessed 4.9.21).

4 Bukti konfirmasi review ke dua dan hasil review 21 Januari 2022



Bioprospecting of bacterial symbionts of sponge *Spongia officinalis* from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

Abstract. Marine sponge *Spongia* sp. has been reported to have potential as an antibacterial agent. However, less information on the potential of bacterial symbionts of *Spongia* sp. as an antibacterial agent has been documented. To minimize this research gap, focused this

research on the bacterial isolates of *S. officinalis* which have antibacterial activity against multidrug resistance (MDR)-bacteria isolated from clinical specimens. *S. officinalis* was collected from Savu Sea, East Nusa Tenggara, Indonesia and its symbionts were isolated with Zobell marine agar media. The overlay method was used to screen the antibacterial activity against selected six MDR bacteria. Antibacterial activity was determined by measuring the diameter of the inhibition zone. Identification of active bacterial symbionts was carried out based on the 16S rRNA gene sequencing. The results revealed that four out of 10 symbionts showed antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *Escherichia coli* and ESβL + CRE- *Klebsiella pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate showed antibacterial activity against CRPA. The selected four isolated were identified as *Bacillus subtilis*, *B. mojavenensis* and *B. simplex* using 16S rRNA gene sequencing and BLASTn analysis. These results provide information about the potential of bacterial symbionts of *S. officinalis* as natural antibacterial sources against MDR bacteria.

Keyword: Antibacterial, Multidrug-resistant, bacterial symbionts, sponge, *Spongia officinalis*.

INTRODUCTION

Infectious disease attributed to multidrug resistance (MDR) bacteria has become a health problem throughout the world including Indonesia. The use of antibiotics without following the guidelines is one of the causes of bacterial resistance to antibiotics (Bologa et al., 2013). Patients infected with MDR bacteria have a high risk due to difficult treatment and the need for more sources of treatment compared to the patients suffering from infections that are not related to MDR (Word Health Organization, 2018). The Center for Diseases Control and Prevention (CDC) identifies the top MDR bacteria based on their threats. Several pathogenic bacteria such as methicillin-resistant, ESβL-producing Enterobacteriaceae, carbapenemase-resistant and Vancomycin-resistant are considered to be MDR bacteria that cause serious dangers (CDC, 2019).

Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common resistant bacterium and is the main cause of nosocomial infections worldwide, including in Indonesia. The prevalence rate of MRSA in hospitals in several Asian countries such as Korea, Japan, South, Taiwan, and China is 70–80% (Song et al., 2011). The carriage MRSA rate is 4.3% (64 of 1,502) among surgery patients at discharge from Indonesian hospitals (Mayer et al., 2010). Meanwhile, the resistance of Enterococci bacteria to the vancomycin group has also become a serious problem. The emergence of the vancomycin-resistant *Enterococci* (VRE)- *Enterococcus faecalis* strains has caused great difficulties in antibiotic therapy (Adhikari, 2010).

β-lactam is the most commonly used antibiotic to fight against infection caused Gram-negative bacteria, so many Gram-negative bacteria are resistant to β-lactam antibiotics. ESβL–producing Enterobacteriaceae, especially *Escherichia coli* and *Klebsiella pneumoniae* subsp *pneumoniae* have increased dramatically over the past few years (Kim et al., 2002). Nearly 30% of ESβL-producing *K. pneumoniae* were identified from the total positive cultures in clinical specimens of patients at a hospital in South Sulawesi, Indonesia (Waworuntu et al., 2021). The resistance of Gram-negative bacteria to the Carbapenem class antibiotics has entered the critical list (WHO, 2017) and a natural antibacterial agent is required to be taken from a biological source.

Natural anti-MDR bacterial agents can be obtained from fruits (Prastiyanto et al., 2020d), seeds (Prastiyanto et al., 2020a; Prastiyanto, 2021), Latex (Prastiyanto et al., 2020c) lactic acid bacteria (Lestari et al., 2019), mushroom (Prastiyanto et al., 2020b, 2016), and bacterial isolates from marine organisms (Al-dhabi et al., 2020). In recent years, there have been many studies on bioactive compounds from marine sources (Webster and Taylor, 2012). The bioactive potential of marine sources is effective in fighting pathogens that infect humans (Blunt et al., 2017). Marine organisms including sponges, corals, Cnidaria, Arthropods, Echinodermata, and Tunicates have attracted the attention of many scientists over the past few decades because of the beneficial bioactive compounds producers (Nalini et al., 2018; Radjasa et al., 2013, 2011). Sponges are one of the most potential marine organisms that have the potential for bioactive compounds. The bioactive compounds have been used as the sources of drugs such as anti-tumor, anti-cancer, anti-inflammatory, cytotoxic, anti-malarial, antifouling, immunosuppressive, antiviral, antifungal, and antibacterial (Mayer et al., 2010).

Commented [Ajar Nath25]: Reframe for correctness

Commented [Ajar Nath26]: Add more citations here 2-3

Commented [Ajar Nath27]: Reframe for correctness

Commented [Ajar Nath28]: Add 2-3 relevant citations for this

Sponges are marine biota with secondary metabolite compounds potential as an antibacterial agents. Many studies have reported that sponges occupy the highest position of marine life, which shows potential as an antibacterial agents. A novel alkaloid isoaaptamine isolated from the sponge *Aaptos aaptos* inhibits sortase A (SrtA), an enzyme that plays a key role in the retention and virulence of cell wall proteins in *S. aureus* (Jang et al., 2007). Three polybrominated diphenyl ethers are produced from the *Dysidea granulose* (marine sponge). They possessed broad-spectrum activity against methicillin-sensitive *S. aureus* (MSSA) and MRSA (Sun et al., 2015). However, obtaining bioactive compounds from marine sources requires a lot of materials. This will damage the marine ecosystem if the sponge is exploited continuously.

Commented [Ajar Nath29]: Reframe for correctness

Spongia sp. has been reported to have bioactive compounds in the form of merosesquiterpenes, which show antibacterial activity against *S. aureus* (Nguyen et al., 2017). Several studies have recounted that many bioactive compounds from marine life are similar to the bioactive compounds of microorganisms associated with these marine biotas (König et al., 2006). The present investigation deals with isolation of bacterial symbionts of sponge *Spongia officinalis* and characterization antibacterial potential against multidrug-resistant bacteria.

MATERIALS AND METHODS

The collection of sponge samples

Sponge samples were collected approximately from a depth of 1.5 m from Savu Sea, Kupang, East Nusa Tenggara, Indonesia in 8 November 2019 at 10°08'22.0"S 123°37'39.2"E (Figure 1). The obtained samples were then put into sterile bags underwater, stored in a cooler (4°C), and brought to the laboratory. The identification and classification of sponges were carried out in the Diponegoro University Fisheries and Marine Laboratory.

Figure 1: Map of the study areas in the Savu Sea, Kupang, East Nusa Tenggara, Indonesia. A-D, Sampling sites and E, *S. officinalis* collected from the sampling site

Isolation of bacterial symbionts of *Spongia officinalis*

The sponges were processed under aseptic conditions. One gram of *S. officinalis* was rinsed with sterile seawater three times, crushed, and added with 9 mL of sterile seawater. The sponge sample was then diluted with 10^{-4}, 100 µL of which was taken and spread on Zobell marine agar (Marine agar 2216) Himedia® media, and then incubated at 35 ± 2°C for one week. Colonies were selected based on morphological differences. Colonies with different morphologies were transferred to the same media to obtain a pure culture.

Bacterial preparation

Multidrug resistance bacteria were isolated from patients of the hospital Dr. Kariadi, Semarang City, Indonesia (Table 1). All isolates were identified and susceptibility patterns were obtained using Vitek®MS (bioM´erieux). The MDR bacteria were sub-cultured on 5% sheep blood agar plate overnight (24 h) at 35±2°C. The MDR bacterial colonies were homogenized and adjusted to 0.5 McFarland standards (5×10^8 CFU/mL) using McFarland Densitometer.

Table 1: The organisms for *in vitro* antibacterial screening

No	Species	Source	Antibiotic resistance pattern
1	*ESβL- E. coli*	Urine	Ampicillin, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ciprofloxacin, Nitrofurantoin Sulfamethoxazole
2	*ESβL + CR- K. pneumoniae subsp pneumoniae*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ertapenem, Meropenem, Ciprofloxacine, Sulfamethoxazole
3	CRPA	Sputum	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin Gentamicin, Ciprofloxacin, Tigecycline, Nitrofurantoin, Sulfamethoxazole
4	*MDRO-Acinetobacter baumanii*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin, Gentamicin, Ciprofloxacine, Sulfamethoxazole
5	MRSA	Wound	Benzylpenicillin, Oxacillin, Gentamicin, Ciprofloxacin, Levofloxacin, Moxifloxacin, Nitrofurantoin, Sulfamethoxazole
6	*VRE Enterococcus faecalis*	Urine	Gentamicin, Streptomycin, Ciprofloxacin, Levofloxacin, Erythromycin, Dalfopristin, Vancomycin, Tetracycline

Note: ESβL: extended-spectrum beta-lactamase, CR: Carbapenem-resistant, CRPA: Carbapenem-resistant Pseudomonas aeruginosa, MDRO: Multidrug-Resistant Organisms, MRSA: Methicillin-resistant Staphylococcus aureus, VRE: Vancomycin-resistant Enterococci

Screening for antibacterial activities against MDR bacteria

Screening to determine the antibacterial activity against MDR bacteria was carried out using the overlay method (Radjasa et al., 2013). The pure culture was inoculated ± 1 cm2 on Zobell marine agar medium in triplicate. After the bacteria grew, depending on the growth rate of the bacteria, which was commonly 1-7 days, the surface of the media was covered with Muller Hilton soft agar (0.3% (w/v) Muller Hilton broth, 1% (w/v) NaCl and 0.7% (w/v) agar containing 1% (v/v) MDR bacteria (ESβL- *E. coli*, ESβL+CRE- *K. pneumoniae* subsp *pneumonia*e, CRPA, MRSA, and VRE- *E. faecalis*.

All the plates were then incubated aerobically at 35 ± 2°C for 24 hours. Antibacterial activity of the isolates were determined by measuring the diameter of the inhibition zone in mm around the bacterial isolates. The levels of antibacterial activity were categorized as follows: no antibacterial activity (-), 0-1 mm (+), 1-3 mm (++), 3-7 mm (+++) and 7-15 mm (++++) (Asagabaldan et al., 2019). The inhibition area was measured to confirm the antibacterial activity (Apsari et al., 2019).

$$\text{Inhibition index (II)} = \frac{\text{Diameter inhibition area (mm)} - \text{diameter colony (mm)}}{\text{Diameter colony (mm)}}$$

Molecular identification of active bacterial symbionts of *S. officinalis*

DNA was extracted from bacterial cells (up to 1 x 10^9) using Presto™ Mini g DNA Bacteria Kit (Geneaid) according to the appropriate protocols in the manufacturer's instructions, with a final elution volume of 50 µL. Extracted DNA was stored at 4°C until required for PCR. The concentration of bacterial DNA used was 50 ng/µL. The volume of bacterial DNA was 2 µL and mix with 16S rRNA gene primer. This step using 2 µL of 16S rRNA gene primer 27F '5'-AGAGTTGATCMTGGCTCAG-3' and 2 µL of 16S rRNA gene primer 1492R '5'-CGGTTACCTTGTTACGACTT-3'. The final concentration of 10 µM primer was 10 µM. Formulation mixing are nuclease free water 6,5 µL, master mix (Promega) 12,5 µL, primer and DNA template. The amplification conditions of both PCRs were as follows. The heat started to activate the Taq polymerase enzyme at a temperature of 95°C for 4 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, primer annealing at 57°C for 30 seconds, extension at 72°C for 2 minutes, an extra extension for 72°C at 10 minutes, and cooling down at 4°C for 10 minutes on a Biometra Thermal cycler. PCR products were separated on a 2% agarose gel and DNA bands were visualized with Flourovue. Four microlitters of FluoroVue was added to a mixture of 1 g agarose and 100 ml TAE. PCR product sequencing was carried out by Genetica Science Tangerang to analyze 16S rRNA gene sequences, then the tracking results through the Basic Local Alignment Search Tool (BLAST) database program at the National Center for Biotechnology Information NCBI), National Institute for Health, USA (www.ncbi.nlm.nih.gov) were deposited to GenBank to obtain accession numbers.

Commented [Ajar Nath30]: What is exact value???

Commented [Ajar Nath31]: What is exact value???

Commented [Ajar Nath32]: Give the accession numbers in result section of all 4 bacteria

Phylogenetic analysis

MEGA X software was used for phylogenetic analysis. The results of 16S rRNA gene sequencing were aligned using ClustalW. The phylogenetic trees were determined by the neighbor-joining method with Tamura-Nei model and completed with Non-parametric bootstrapping analysis (1000 datasets) from 16S rRNA gene sequences showing the phylogenetic relationships of closely related strains database available at NCBI GenBank..

RESULTS AND DISCUSSION

Bacterial symbionts of *Spongia officinalis*

The isolation of bacterial symbiont of *S. officinalis* resulted in 10 isolates (Figure 2). The outcomes showed different characters of bacterial isolates. The five out of 10 isolates were rod-shaped, Gram-positive, and endospore-forming. Four isolates were rod-shaped, Gram-positive, non-endospore-forming, while one isolate showed Gram-negative coccus (Table 2).



Figure 2. Macroscopic morphology of bacteria isolated from *S. officinalis* on Zobell marine agar

Table 2. Morphology and Gram staining of bacteria isolated from *S. officinalis*

Isolate	Morphology colony			Gram staining
	Form	Margin	Elevation	
Prastiyanto-1A	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1B	Irregular	Undulate	Convex	Rod-shaped, Gram-negative, endospore-forming
Prastiyanto-1C	Circular	Entire	Convex	Coccus Gram-negative
Prastiyanto-1D	Irregular	Erose	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1E	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-2A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-3A	Irregular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4B	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4C	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Antibacterial activities against MDR bacteria

Antibacterial activity against MDR bacteria of bacterial of *S. officinalis* is indicated by the presence of an inhibition zone (Figure 3). The inhibition zone is a qualitative way to determine the ability of an antimicrobial agent to inhibit the growth of microorganisms, particularly the MDR bacteria. The results of this study revealed that four (40%) of 10 isolates showed antibacterial activity against MDR bacteria. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *E. coli* and ESβL+CRE- *K. pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate proved antibacterial activity against CRPA.



Figure 3. Zones of inhibition of bacteria isolated from *S. officinalis* against MDR bacteria: (a) ESβL- *E. coli*, (b) ESβL + CRE-*K. pneumoniae* subsp *pneumonia*, (c) MRSA, and (d) CRPA. → Zone of inhibition, → colony of bacteria isolated from *S. officinalis*

Identification of bacteria symbionts of *S. officinalis*

Identification of the active bacterial symbionts *S. officinalis* that showed antibacterial activity against MDR was performed based on the 16S rRNA gene (Figure 4). The results showed that four isolates having antibacterial activity against MRD bacteria belonged to the members of the *Bacillus* genus. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. Prastiyanto-1E isolate with *B. subtilis* PBBBS1, Prastiyanto-4A isolate with *B. mojavensis* ifo 15718 and Prastiyanto-2A isolate was closely related to *B. simplex* K1-6

Table 3. Antibacterial activities of bacteria isolated from *S. officinalis* against multidrug-resistant bacteria

Isolate	MDR bacteria											
	ESβL- *E. coli*		ESβL + CRE-*K. pneumoniae* subsp *pneumoniae*		CRPA		MDRO- *A. baumanii*		MRSA		VRE-*E. faecalis*	
	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)	Levels of activity	II (mm)
Prastiyanto-1A	+++	6.4	++++	7.7	-	-	-	-	-	-	-	-
Prastiyanto-1B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1C	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1D	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1E	+++	6.1	++++	9.2	-	-	-	-	-	-	-	-
Prastiyanto-2A	-	-	-	-	-	-	-	-	++++	12.6	-	-
Prastiyanto-3A	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4A	-	-	-	-	+++	4.8	-	-	-	-	-	-
Prastiyanto-4B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4C	-	-	-	-	-	-	-	-	-	-	-	-

Note**:** - denotes no effect

Phylogenetic analyses

Phylogenetic analysis showed that all strains related to the genera validly described species originating from marine habitats. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. *B. subtilis* SWI4a was a bacterium isolated from seaweed *Anthophycus longifolius* and has antibacterial activity (Chakraborty et al., 2014).



Figure 4. Neighbor-joining tree constructed with Tamura-Nei model from 16S rRNA gene sequences showing the phylogenetic relationships of strains from this study to closely related species

Commented [Ajar Nath33]: Give the strain number i.e. Prastiyanto-1A and follow the same for all four

(Don't give S. officinalis-Associated isolate)

The total of 10 strains was selected for isolation of pure cultures according to morphology colony and Gram staining (Table 2). Forty percent (4 isolates) of the total isolates showed inhibitory activities against MDR bacteria (Table 3).The results are in line with the findings of previous studies. Trianto et al. (2019) reported that 324 bacterial isolates associated with 55 sponges (isolates and Sponges ratio of 5.1-10.5) were produced. According to Webster and Thomas (2016), the diversity level of bacteria associated with sponges greatly varies among sponge species. Characterization of bacterial isolates associated with *S. officinalis* was carried out macroscopically (colony morphology) and microscopic (Gram staining).

Commented [Ajar Nath34]: What is meaning here

Give some relevant citations here and discussed same

The results of this study proved that Prastiyanto-1A, Prastiyanto-1E, Pratiyanto-2A and Prastiyanto-4A isolates associated with *S. officinalis* indicated antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. These findings are consistent with the results of previous studies regarding the antibacterial activity of *S. officinalis* extract. *S. officinalis* extract with methanol-toluene solvent was able to inhibit the growth of *S. epidermidis* (5-12 mm), *Streptococcus lactis* (5-12 mm), and *Bacillus subtilis* (2-5 mm) (McCaffrey and Endean, 1985).

Relevant studies reported that extracts of *S. officinalis* could inhibit *S. aureus* and *P. aeruginosa* (Gonaález et al., 1982). Moreover, it was also reported that microorganisms associated with marine biota are the producers of bioactive compounds (König et al., 2006). Davidson and Haygood (1999) confirmed that the producer of the bryostatin compound from *Bugula neritina* was the microbial symbionts of *Candidatus Endobugula sertula*. The antibacterial activity against MDR bacteria belonged to the members of the *Bacillus* genus. Previous studies on bacteria associated with *Spongia* have shown similar results (Odekina et al., 2020). According to Mondol et al. (2013) *Bacillus* isolated from the sea produces secondary metabolites various antimicrobial activities (Mondol et al., 2013).

Phylogenetic analysis showed that Prastiyanto-1E isolate *B. subtilis* PBBBS1, a bacterium isolated from the marine sediments of the Burmanallah coast (Cherian et al., 2019). Prastiyanto-4A isolate was very much linked to *B. mojavensis* ifo 15718, which was distilled from the sea and had antimicrobial potential (Ma et al., 2012) while Prastiyanto-2A isolate was associated with *B. simplex* K1-6 isolated from a coastal city, Izmir, Turkey.(Cherian et al., 2019) The bioactive compounds of all isolates that have the potential to act as anti-bacterial agents against MDR bacteria in this study have not been investigated. However, several studies have reported the antibacterial potential of the *Bacillus* genus members. *Surfactin* produced by *B. subtilis* C9 exhibits antibacterial and antiviral activities (Kim et al., 1997). MacrolactinW extracted from ethyl acetate fraction from the fermentation of *Bacillus* sp. 09ID194 isolated from the sea showed strong antibacterial activity against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Mondol et al., 2011).

In conclusion, the bacterial symbionts of *S. officinalis* potential as antibacterial agents against MDR bacteria belong to *Bacillus*. These results provide information about the potential of bacteria associated with *S. officinalis* as natural antibacterial sources against MDR bacteria.

ACKNOWLEDGMENTS

The authors would like to thank Gaudensius U.U. Boli Duhan, M.Sc. from Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Katolik Widya Mandira, Kupang, Indonesia for help during sampling on Savu Sea, Kupang, East Nusa Tenggara, Indonesia

REFERENCES

Adhikari L. 2010. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial *Enterococci*. J. Clob. Infect. Dis. 2, 231–235. https://doi.org/10.4103/0974-777X.68534

Al-dhabi NA., Esmail GA., Ghilan AM, Arasu MV, Duraipandiyan V, Ponmurugan K. 2020. Chemical constituents of *Streptomyce*s sp. strain Al-Dhabi-97 isolated from the marine region of Saudi Arabia with antibacterial and anticancer properties. J. Infect. Public Health 13, 235–243.

Apsari PP, Budiarti SRI, Wahyudi ATRI. 2019. *Actinomycetes* of rhizosphere soil producing antibacterial compounds against urinary tract infection bacteria. Biodiversitas 20, 1259–1265. https://doi.org/10.13057/biodiv/d200504

Asagabaldan MA, Bedoux G, Bourgougnon N. 2019. Bacterial isolates from bryozoan *Pleurocodonellina* sp .: Diversity and antimicrobial potential against pathogenic bacteria. Biodiversitas 20, 2528–2535. https://doi.org/10.13057/biodiv/d200914

Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR. 2017. Marine natural products. Nad prod Rep 34, 235–294. https://doi.org/10.1039/c4np00144c

Bologa CG, Ursu O, Oprea T. Melançon CE, Tegos G. 2013. Emerging trends in the discovery of natural product antibacterials cristian. Curr. Opin. Pharmacol. 13, 678–687. https://doi.org/10.1016/j.cortex.2009.08.003.Predictive

CDC. 2019. Biggest Threats and Data 2019 AR Threats Report [WWW Document]. Centers Diesease Control Prev.

Chakraborty K, Thilakan B, Raola VK. 2014. Polyketide family of novel antibacterial 7-O-methyl-5′-hydroxy-3′-heptenoate-macrolactin from seaweed-associated *Bacillus subtilis* MTCC 10403. J. Agric. Food Chem. https://doi.org/10.1021/jf504845m

Cherian T, Yalla S, Mohanraju R. 2019. Antimicrobial potential of methanolic extract of *Bacillus aquimaris* isolated from the marine waters of Burmanallah coast, South Andaman. Int J Biopharm Res 8(12), 2806–2813. https://doi.org/10.21746/ijbpr.2019.8.12.1

Davidson SK, Haygood MG. 1999. Identification of sibling species of the bryozoan *Bugula neritina* that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "*Candidatus Endobugula sertula*". Biol Bull 196, 273–80. https://doi.org/10.2307/1542952

Gonaález AG, Darias V, Estévez E. 1982. Contribution to the biological study of *Spongia officinalis*. Farm. Sci. 37, 179–83.

Jang KH, Chung SC, Shin J, Lee SH, Kim TI, Lee HS, Oh KB. 2007. Aaptamines as sortase A inhibitors from the tropical sponge *Aaptos aaptos*. Bioorganic Med. Chem. Lett. 17, 5366–5369. https://doi.org/10.1016/j.bmcl.2007.08.007

Kim HS, Yoon BD, Lee CH, Suh HH, Oh HM, Katsuragi T, Tani Y. 1997. Production and properties of a lipopeptide biosurfactant from *Bacillus subtilis* C9. J. Ferment. Bioeng. 84, 41–46. https://doi.org/10.1016/S0922-338X(97)82784-5

Kim Y, Pai H, Lee H, Park S, Choi E, Kim-Jungmin. 2002. Bloodstream infections by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in children : epidemiology and clinical outcome. Antimicrob. Agents Chemother. 46, 1481–1491. https://doi.org/10.1128/AAC.46.5.1481

König GM, Kehraus S, Seibert SF, Abdel-lateff A, Müller D. 2006. Natural products from marine organisms and their associated microbes. Chembiochem 7, 229–38. https://doi.org/10.1002/cbic.200500087

Lestari SD, Sadiq ALO, Safitri WA, Dewi SS, Prastiyanto ME. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. J. Phys. Conf. Ser. 1375, 012021. https://doi.org/10.1088/1742-6596/1374/1/012021

Ma Z, Wang N, Hu J, Wang S. 2012. Isolation and characterization of a new iturinic lipopeptide, mojavensin A produced by a marine-derived bacterium *Bacillus mojavensis* B0621A. J. Antibiot. (Tokyo). 65, 317–322. https://doi.org/10.1038/ja.2012.19

Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. 2010. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31, 255–265. https://doi.org/10.1016/j.tips.2010.02.005

McCaffrey EJ, Endean R. 1985. Antimicrobial activity of tropical and subtropical sponges. Mar. Biol. 89, 1–8.

Mondol MAM, Kim JH, Lee HS, Lee YJ, Shin HJ. 2011. Macrolactin W, a new antibacterial macrolide from a marine *Bacillus* sp. Bioorganic Med. Chem. Lett. 21, 3832–3835. https://doi.org/10.1016/j.bmcl.2010.12.050

Mondol MAM, Shin HJ, Islam MT. 2013. Diversity of secondary metabolites from marine *Bacillus* species: Chemistry and biological activity. Mar. Drugs 11, 2846–2872. https://doi.org/10.3390/md11082846

Nalini S, Richard DS, Riyaz SUM, Kavitha G, Inbakandan D. 2018. Antibacterial macro molecules from marine organisms. Int. J. Biol. Macromol. 115, 696–710. https://doi.org/10.1016/j.ijbiomac.2018.04.110

Nguyen MH, Ito T, Kurimoto S, Ogawa M, Nwet N, Quoc V, Thi H, Kubota T, Morita H. 2017. New merosesquiterpenes from a Vietnamese marine sponge of *Spongia* sp . and their biological activities. Bioorg. Med. Chem. Lett. 27, 3043–3047. https://doi.org/10.1016/j.bmcl.2017.05.060

Odekina PA, Agbo MO, Omeje EO. 2020. Antimicrobial and antioxidant activities of novel marine bacteria (*Bacillus* 2011SOCCUF3) isolated from marine sponge (*Spongia officinalis*). Pharm. Sci. 26, 82–87. https://doi.org/10.34172/PS.2019.59

Prastiyanto ME. 2021. Seeds extract of three *Artocarpus* species : Their in-vitro antibacterial activities against multidrug-resistant (MDR) *Escherichia coli* isolates from urinary tract infections (UTIs). Biodiversitas 22, 4356–4362. https://doi.org/10.13057/biodiv/d221028

Prastiyanto ME, Azizah IH, Haqi HD, Yulianto BD, Agmala AB, Radipasari ZD, Astuti NAD. 2020a. In-vitro antibacterial activity of the seed extract of three member *Artocarpus* towards methicillin resistant *Staphylococcus aureus* (MRSA). J. Teknol. Lab. 9, 1–6. https://doi.org/10.29238/tek

Prastiyanto ME, Rukmana RM, Saraswati DK, Darmawati S, Maharani ETW, Tursinawati Y, 2020b. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and antibacterial activity against Methicillin-Resistant *Staphylococcus aureus*. Biodiversitas 21, 5644–5649. https://doi.org/10.13057/biodiv/d211221

Prastiyanto ME, Setyaningtyas A, Trisnawati L, Syafira A. 2016. Antimicrobial activity and identification the compounds of methanol extract from the *Pleurotus ostreatus* fruiting body. El-Hayah: Jurnal Biologi 6, 29-34. https://doi.org/10.18860/elha.v6i1.4082

Prastiyanto ME, Tama PD, Ananda N, Wilson W, Mukaromah AH. 2020c. Antibacterial potential of *Jatropha* sp. latex against Multidrug-Resistant bacteria. Int. J. Microbiol. 2020. https://doi.org/10.1155/2020/8509650

Prastiyanto ME, Wardoyo FA, Wilson W, Darmawati S. 2020d. Antibacterial activity of various extracts of *Averrhoa bilimbi* against multidrug resistant bacteria. Biosaintifika 12, 163–168.

Radjasa OK, Khoeri MM, Darusallam CC, Trimasanto H, Sudoyo H. 2013. Bacterial symbionts of reef invertebrates: Screening for anti-pathogenic bacteria activity. Biodiversity 14, 80–86. https://doi.org/10.1080/14888386.2013.774937

Radjasa OK, Vaske YM, Navarro G, Vervoort HC, Tenney K, Linington RG, Crews P. 2011. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg Med Chem. 19, 6658–6674. https://doi.org/10.1016/j.bmc.2011.07.017.Highlights

Song J, Hsueh P, Chung DR, Ko KS, Kang C, Peck KR. 2011. Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : An ANSORP study Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : an ANSORP. J Antimicrob Chemother 66, 1062–1069. https://doi.org/10.1093/jac/dkr024

Sun S, Canning CB, Bhargava K, Sun X, Zhu W, Zhou N, Zhang Y, Zhou K. 2015. Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge *Dysidea*. Bioorganic Med. Chem. Lett. 25, 2181–2183. https://doi.org/10.1016/j.bmcl.2015.03.057

Waworuntu O, Sjahril R, Rasita YD, Munawir M. 2021. Characteristic of extended-spectrum-B-lactamase (ESBL) Producing *Klebsiella pneumoniae* at tertiary referral hospital in South Sulawesi, Indonesia. Int. J. Infect. Dis. 101, 80. https://doi.org/10.1016/j.ijid.2020.09.236

Webster NS, Taylor MW. 2012. Marine sponges and their microbial symbionts : love. Environ. Microbiol. 14, 335–346. https://doi.org/10.1111/j.1462-2920.2011.02460.x

Word Health Organization. 2017. Essential medicines and health products Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. (accessed 4.9.21)

Word Health Organization. 2018. Resistance in bacteria Antibiotic. URL http://www.who.int/mediacentre/factsheets/fs194/en/ (accessed 4.9.21).

5 Bukti konfirmasi submit revisi ke dua dan artikel yang diresubmit (24 Januari 2022)



Bioprospecting of bacterial symbionts of sponge *Spongia officinalis* from Savu Sea, East Nusa Tenggara, Indonesia for antibacterial potential against multidrug-resistant bacteria

Abstract. Marine sponge *Spongia* sp. has been reported to have potential as an antibacterial agent. However, less information on the potential of bacterial symbionts of *Spongia* sp. as an antibacterial agent has been documented. The present investigation deals with isolation of bacterial symbionts of sponge *Spongia officinalis* and characterization antibacterial potential against multidrug-resistant bacteria. isolated from clinical specimens. *S. officinalis* was collected from Savu Sea, East Nusa Tenggara, Indonesia and its symbionts were isolated with Zobell marine agar media. The overlay method was used to screen the antibacterial activity against selected six MDR bacteria. Antibacterial activity was determined by measuring the diameter of the inhibition zone. Identification of active bacterial symbionts was carried out based on the 16S rRNA gene sequencing. The results revealed that four out of 10 symbionts showed antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *Escherichia coli* and ESβL + CRE- *Klebsiella pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate showed antibacterial activity against CRPA. The selected four isolated were identified as *Bacillus subtilis*, *B. mojavenensis* and *B. simplex* using 16S rRNA gene sequencing and BLASTn analysis. These results provide information about the potential of bacterial symbionts of *S. officinalis* as natural antibacterial sources against MDR bacteria.

Commented [Ajar Nath35]: Reframe for correctness

Keyword: Antibacterial, Multidrug-resistant, bacterial symbionts, sponge, *Spongia officinalis*.

INTRODUCTION

Infectious disease attributed to multidrug resistance (MDR) bacteria has become a health problem throughout the world including Indonesia. The use of antibiotics without following the guidelines is one of the causes of bacterial resistance to antibiotics (Bologa et al., 2013). Patients infected with MDR bacteria have a high risk due to difficult treatment and the need for more sources of treatment compared to the patients suffering from infections that are not related to MDR (Word Health Organization, 2018). The Center for Diseases Control and Prevention (CDC) identifies the top MDR bacteria based on their threats. Several pathogenic bacteria such as methicillin-resistant, ESβL-producing Enterobacteriaceae, carbapenemase-resistant and Vancomycin-resistant are considered to be MDR bacteria that cause serious dangers (CDC, 2019).

Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common resistant bacterium and is the main cause of nosocomial infections worldwide, including in Indonesia. The prevalence rate of MRSA in hospitals in several Asian countries such as Korea, Japan, South, Taiwan, and China is 70–80% (Song et al., 2011). The carriage MRSA rate is 4.3% (64 of 1,502) among surgery patients at discharge from Indonesian hospitals (Mayer et al., 2010). Meanwhile, the resistance of Enterococci bacteria to the vancomycin group has also become a serious problem. The emergence of the vancomycin-resistant *Enterococci* (VRE)- *Enterococcus faecalis* strains has caused great difficulties in antibiotic therapy (Adhikari, 2010).

β-lactam is the most commonly used antibiotic to fight against infection caused Gram-negative bacteria, so many Gram-negative bacteria are resistant to β-lactam antibiotics. ESβL–producing Enterobacteriaceae, especially *Escherichia coli* and *Klebsiella pneumoniae* subsp *pneumoniae* have increased dramatically over the past few years (Kim et al., 2002; Bayraktar et al., 2019). Nearly 30% of ESβL-producing *K. pneumoniae* were identified from the total positive cultures in clinical specimens of patients at a hospital in South Sulawesi, Indonesia (Waworuntu et al., 2021). The resistance of Gram-negative bacteria to the Carbapenem class antibiotics has entered the critical list (WHO, 2017) and a natural antibacterial agent is required to be taken from a biological source.

Natural anti-MDR bacterial agents can be obtained from fruits (Prastiyanto et al., 2020d), seeds (Prastiyanto et al., 2020a; Prastiyanto, 2021), Latex (Prastiyanto et al., 2020c) lactic acid bacteria (Lestari et al., 2019), mushroom (Prastiyanto et al., 2020b, 2016), and bacterial isolates from marine organisms (Al-dhabi et al., 2020). In recent years, studies of marine bioactive compounds have yielded a considerable number of drug candidates (Webster and Taylor, 2012). The bioactive potential of marine sources is effective in fighting pathogens that infect humans (Blunt et al., 2017). Marine organisms including sponges, corals, Cnidaria, Arthropods, Echinodermata, and Tunicates have attracted the attention of many scientists over the past few decades because of the beneficial bioactive compounds producers (Nalini et al., 2018; Radjasa et al., 2013, 2011). Sponges are one of the most potential marine organisms that have the potential for bioactive compounds. The bioactive compounds have been used as the sources of drugs such as anti-tumor, anti-cancer, anti-inflammatory, cytotoxic, anti-malarial, antifouling, immunosuppressive, antiviral, antifungal, and antibacterial (Mayer et al., 2010; Anjum et al., 2016).

Many studies have reported that sponges occupy the highest position of marine life, which shows potential as an antibacterial agents. A novel alkaloid isoaaptamine isolated from the sponge *Aaptos aaptos* inhibits sortase A (SrtA), an enzyme that plays a key role in the retention and virulence of cell wall proteins in *S. aureus* (Jang et al., 2007). Three polybrominated diphenyl ethers are produced from the *Dysidea granulose* (marine sponge). They possessed broad-spectrum activity against methicillin-sensitive *S. aureus* (MSSA) and MRSA (Sun et al., 2015). However, obtaining bioactive compounds from marine sources requires a lot of materials. This will damage the marine ecosystem if the sponge is exploited continuously.

Commented [Ajar Nath36]: Add more citations here 2-3

Commented [Ajar Nath37]: Add 2-3 relevant citations for this

Spongia sp. has been reported to have bioactive compounds in the form of merosesquiterpenes, which show antibacterial activity against *S. aureus* (Nguyen et al., 2017). Several studies have recounted that many bioactive compounds from marine life are similar to the bioactive compounds of microorganisms associated with these marine biotas (König et al., 2006). The present investigation deals with isolation of bacterial symbionts of sponge *Spongia officinalis* and characterization antibacterial potential against multidrug-resistant bacteria.

MATERIALS AND METHODS

The collection of sponge samples

Sponge samples were collected approximately from a depth of 1.5 m from Savu Sea, Kupang, East Nusa Tenggara, Indonesia in 8 November 2019 at 10°08'22.0"S 123°37'39.2"E (Figure 1). The obtained samples were then put into sterile bags underwater, stored in a cooler (4°C), and brought to the laboratory. The identification and classification of sponges were carried out in the Diponegoro University Fisheries and Marine Laboratory.

Figure 1: Map of the study areas in the Savu Sea, Kupang, East Nusa Tenggara, Indonesia. A-D, Sampling sites and E, *S. officinalis* collected from the sampling site

Isolation of bacterial symbionts of *Spongia officinalis*

The sponges were processed under aseptic conditions. One gram of *S. officinalis* was rinsed with sterile seawater three times, crushed, and added with 9 mL of sterile seawater. The sponge sample was then diluted with 10^{-4}, 100 µL of which was taken and spread on Zobell marine agar (Marine agar 2216) Himedia® media, and then incubated at 35 ± 2°C for one week. Colonies were selected based on morphological differences. Colonies with different morphologies were transferred to the same media to obtain a pure culture.

Bacterial preparation

Multidrug resistance bacteria were isolated from patients of the hospital Dr. Kariadi, Semarang City, Indonesia (Table 1). All isolates were identified and susceptibility patterns were obtained using Vitek®MS (bioM´erieux). The MDR bacteria were sub-cultured on 5% sheep blood agar plate overnight (24 h) at 35±2°C. The MDR

bacterial colonies were homogenized and adjusted to 0.5 McFarland standards (5×10^8 CFU/mL) using McFarland Densitometer.

Table 1: The organisms for *in vitro* antibacterial screening

No	Species	Source	Antibiotic resistance pattern
1	*ESβL- E. coli*	Urine	Ampicillin, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ciprofloxacin, Nitrofurantoin Sulfamethoxazole
2	*ESβL + CR- K. pneumoniae subsp pneumoniae*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Ertapenem, Meropenem, Ciprofloxacine, Sulfamethoxazole
3	CRPA	Sputum	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin Gentamicin, Ciprofloxacin, Tigecycline, Nitrofurantoin, Sulfamethoxazole
4	*MDRO-Acinetobacter baumanii*	Urine	Ampicillin, Sulbactam, Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Amikacin, Gentamicin, Ciprofloxacine, Sulfamethoxazole
5	MRSA	Wound	Benzylpenicillin, Oxacillin, Gentamicin, Ciprofloxacin, Levofloxacin, Moxifloxacin, Nitrofurantoin, Sulfamethoxazole
6	*VRE Enterococcus faecalis*	Urine	Gentamicin, Streptomycin, Ciprofloxacin, Levofloxacin, Erythromycin, Dalfopristin, Vancomycin, Tetracycline

Note: ESβL: extended-spectrum beta-lactamase, CR: Carbapenem-resistant, CRPA: Carbapenem-resistant Pseudomonas aeruginosa, MDRO: Multidrug-Resistant Organisms, MRSA: Methicillin-resistant Staphylococcus aureus, VRE: Vancomycin-resistant Enterococci

Screening for antibacterial activities against MDR bacteria

Screening to determine the antibacterial activity against MDR bacteria was carried out using the overlay method (Radjasa et al., 2013). The pure culture was inoculated ± 1 cm2 on Zobell marine agar medium in triplicate. After the bacteria grew, depending on the growth rate of the bacteria, which was commonly 1-7 days, the surface of the media was covered with Muller Hilton soft agar (0.3% (w/v) Muller Hilton broth, 1% (w/v) NaCl and 0.7% (w/v) agar containing 1% (v/v) MDR bacteria (ESβL- *E. coli*, ESβL+CRE- *K. pneumoniae* subsp *pneumonia*e, CRPA, MRSA, and VRE- *E. faecalis*.

All the plates were then incubated aerobically at 35 ± 2°C for 24 hours. Antibacterial activity of the isolates were determined by measuring the diameter of the inhibition zone in mm around the bacterial isolates. The levels of antibacterial activity were categorized as follows: no antibacterial activity (-), 0-1 mm (+), 1-3 mm (++), 3-7 mm (+++) and 7-15 mm (++++) (Asagabaldan et al., 2019). The inhibition area was measured to confirm the antibacterial activity (Apsari et al., 2019).

$$\text{Inhibition index (II)} = \frac{\text{Diameter inhibition area (mm)} - \text{diameter colony (mm)}}{\text{Diameter colony (mm)}}$$

Molecular identification of active bacterial symbionts of *S. officinalis*

DNA was extracted from bacterial cells (up to 1×10^9) using Presto™ Mini g DNA Bacteria Kit (Geneaid) according to the appropriate protocols in the manufacturer's instructions, with a final elution volume of 50 µL. Extracted DNA was stored at 4°C until required for PCR. The concentration of bacterial DNA used was 50 ng/µL. The volume of bacterial DNA was 2 µL and mix with 16S rRNA gene primer. This step using 2 µL of 16S rRNA gene primer 27F '5'-AGAGTTGATCMTGGCTCAG-3' and 2 µL of 16S rRNA gene primer 1492R '5'-CGGTTACCTTGTTACGACTT-3'. The final concentration of 10 µM primer was 10 µM. Formulation mixing are nuclease free water 6.5 µL, master mix (Promega) 12.5 µL, primer and DNA template. The amplification conditions of both PCRs were as follows. The heat started to activate the Taq polymerase enzyme at a temperature of 95°C for 4 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, primer annealing at 57°C for 30 seconds, extension at 72°C for 2 minutes, an extra extension for 72°C at 10 minutes, and cooling down at 4°C for 10 minutes on a Biometra Thermal cycler. PCR products were separated on a 2%

agarose gel and DNA bands were visualized with Flourovue. Four microlitters of FluoroVue was added to a mixture of 1 g agarose and 100 ml TAE. PCR product sequencing was carried out by Genetica Science Tangerang to analyze 16S rRNA gene sequences, then the tracking results through the Basic Local Alignment Search Tool (BLAST) database program at the National Center for Biotechnology Information NCBI), National Institute for Health, USA (www.ncbi.nlm.nih.gov)

Phylogenetic analysis

MEGA X software was used for phylogenetic analysis. The results of 16S rRNA gene sequencing were aligned using ClustalW. The phylogenetic trees were determined by the neighbor-joining method with Tamura-Nei model and completed with Non-parametric bootstrapping analysis (1000 datasets) from 16S rRNA gene sequences showing the phylogenetic relationships of closely related strains database available at NCBI GenBank..

RESULTS AND DISCUSSION

Bacterial symbionts of *Spongia officinalis*

The isolation of bacterial symbiont of *S. officinalis* resulted in 10 isolates (Figure 2). The outcomes showed different characters of bacterial isolates. The five out of 10 isolates were rod-shaped, Gram-positive, and endospore-forming. Four isolates were rod-shaped, Gram-positive, non-endospore-forming, while one isolate showed Gram-negative coccus (Table 2).



Figure 2. Macroscopic morphology of bacteria isolated from *S. officinalis* on Zobell marine agar

Table 2. Morphology and Gram staining of bacteria isolated from *S. officinalis*

Isolate	Morphology colony			Gram staining
	Form	Margin	Elevation	
Prastiyanto-1A	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1B	Irregular	Undulate	Convex	Rod-shaped, Gram-negative, endospore-forming
Prastiyanto-1C	Circular	Entire	Convex	Coccus Gram-negative
Prastiyanto-1D	Irregular	Erose	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-1E	Circular	Curled	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-2A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, endospore-forming
Prastiyanto-3A	Irregular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Prastiyanto-4A	Circular	Undulate	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4B	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming
Prastiyanto-4C	Circular	Entire	Convex	Rod-shaped, Gram-positive, non- endospore-forming

Antibacterial activities against MDR bacteria

Antibacterial activity against MDR bacteria of bacterial of *S. officinalis* is indicated by the presence of an inhibition zone (Figure 3). The inhibition zone is a qualitative way to determine the ability of an antimicrobial agent to inhibit the growth of microorganisms, particularly the MDR bacteria. The results of this study revealed that four (40%) of 10 isolates showed antibacterial activity against MDR bacteria. Prastiyanto-1A and Prastiyanto-1E isolates demonstrated antibacterial activity against ESβL- *E. coli* and ESβL+CRE- *K. pneumoniae* subsp *pneumoniae*, Pratiyanto-2A isolate showed antibacterial activity against MRSA, while Prastiyanto-4A isolate proved antibacterial activity against CRPA.



Figure 3. Zones of inhibition of bacteria isolated from *S. officinalis* against MDR bacteria: (a) ESβL- *E. coli*, (b) ESβL + CRE-*K. pneumoniae* subsp *pneumonia*, (c) MRSA, and (d) CRPA. → Zone of inhibition, → colony of bacteria isolated from *S. officinalis*

Identification of bacteria symbionts of *S. officinalis*

Identification of the active bacterial symbionts *S. officinalis* that showed antibacterial activity against MDR was performed based on the 16S rRNA gene (Figure 4). The results showed that four isolates having antibacterial activity against MRD bacteria belonged to the members of the *Bacillus* genus. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. Prastiyanto-1E isolate with *B. subtilis* PBBBS1, Prastiyanto-4A isolate with *B. mojavensis* ifo 15718 and Prastiyanto-2A isolate was closely related to *B. simplex* K1-6

Table 3. Antibacterial activities of bacteria isolated from *S. officinalis* against multidrug-resistant bacteria

Isolate	**MDR bacteria**											
	ESβL- *E. coli*		**ESβL + CRE-*K. pneumoniae* subsp *pneumoniae***		**CRPA**		**MDRO- *A. baumanii***		**MRSA**		**VRE-*E. faecalis***	
	Levels of activity	**II (mm)**	**Levels of activity**	**II (mm)**	**Levels of activity**	**II (mm)**	**Levels of activity**	**II (mm)**	**Levels of activity**	**II (mm)**	**Levels of activity**	**II (mm)**
Prastiyanto-1A	+++	6.4	++++	7.7	-	-	-	-	-	-	-	-
Prastiyanto-1B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1C	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1D	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-1E	+++	6.1	++++	9.2	-	-	-	-	-	-	-	-
Prastiyanto-2A	-	-	-	-	-	-	-	-	++++	12.6	-	-

Prastiyanto-3A	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4A	-	-	-	-	+++	4.8	-	-	-	-	-	-
Prastiyanto-4B	-	-	-	-	-	-	-	-	-	-	-	-
Prastiyanto-4C	-	-	-	-	-	-	-	-	-	-	-	-

Note: - denotes no effect

Phylogenetic analyses

Phylogenetic analysis showed that all strains related to the genera validly described species originating from marine habitats. Prastiyanto-1A isolate demonstrated a close relationship with *B. subtilis* SWI4a. *B. subtilis* SWI4a was a bacterium isolated from seaweed *Anthophycus longifolius* and has antibacterial activity (Chakraborty et al., 2014).



Figure 4. Neighbor-joining tree constructed with Tamura-Nei model from 16S rRNA gene sequences showing the phylogenetic relationships of strains from this study to closely related species

Commented [Ajar Nath38]:
Give the strain number i.e.
Prastiyanto-1A and follow the same for all four

(Don't give S. officinalis-Associated isolate)

The total of 10 strains was selected for isolation of pure cultures according to morphology colony and Gram staining (Table 2). Forty percent (4 isolates) of the total isolates showed inhibitory activities against MDR bacteria (Table 3). Trianto et al. (2019) reported that 324 bacterial isolates associated with 55 sponges (isolates and Sponges ratio of 5.1-10.5) were produced. According to Webster and Thomas (2016), the diversity level of bacteria associated with sponges greatly varies among sponge species. Characterization of bacterial isolates associated with *S. officinalis* was carried out macroscopically (colony morphology) and microscopic (Gram staining).

The results of this study proved that Prastiyanto-1A, Prastiyanto-1E, Pratiyanto-2A and Prastiyanto-4A isolates associated with *S. officinalis* indicated antibacterial activity against MDR bacteria with an inhibition index ranging from 4.8 to 12.6 mm. These findings are consistent with the results of previous studies regarding the antibacterial activity of *S. officinalis* extract. *S. officinalis* extract with methanol-toluene solvent was able to inhibit the growth of *S. epidermidis* (5-12 mm), *Streptococcus lactis* (5-12 mm), and *Bacillus subtilis* (2-5 mm) (McCaffrey and Endean, 1985).

Relevant studies reported that extracts of *S. officinalis* could inhibit *S. aureus* and *P. aeruginosa* (Gonaález et al., 1982). Moreover, it was also reported that microorganisms associated with marine biota are the producers of bioactive compounds (König et al., 2006). Davidson and Haygood (1999) confirmed that the producer of the bryostatin compound from *Bugula neritina* was the microbial symbionts of *Candidatus Endobugula sertula*. The antibacterial activity against MDR bacteria belonged to the members of the *Bacillus* genus. Previous studies on bacteria associated with *Spongia* have shown similar results (Odekina et al., 2020). According to Mondol et al. (2013) *Bacillus* isolated from the sea produces secondary metabolites various antimicrobial activities (Mondol et al., 2013).

Phylogenetic analysis showed that Prastiyanto-1E isolate *B. subtilis* PBBBS1, a bacterium isolated from the marine sediments of the Burmanallah coast (Cherian et al., 2019). Prastiyanto-4A isolate was very much linked to *B. mojavensis* ifo 15718, which was distilled from the sea and had antimicrobial potential (Ma et al., 2012) while Prastiyanto-2A isolate was associated with *B. simplex* K1-6 isolated from a coastal city, Izmir, Turkey.(Cherian et al., 2019) The bioactive compounds of all isolates that have the potential to act as anti-bacterial agents against MDR bacteria in this study have not been investigated. However, several studies have reported the antibacterial potential of the *Bacillus* genus members. *Surfactin* produced by *B. subtilis* C9 exhibits antibacterial and antiviral activities (Kim et al., 1997). MacrolactinW extracted from ethyl acetate fraction from the fermentation of *Bacillus* sp. 09ID194 isolated from the sea showed strong antibacterial activity against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Mondol et al., 2011).

In conclusion, the bacterial symbionts of *S. officinalis* potential as antibacterial agents against MDR bacteria belong to *Bacillus*. These results provide information about the potential of bacteria associated with *S. officinalis* as natural antibacterial sources against MDR bacteria.

ACKNOWLEDGMENTS

The authors would like to thank Gaudensius U.U. Boli Duhan, M.Sc. from Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Katolik Widya Mandira, Kupang, Indonesia for help during sampling on Savu Sea, Kupang, East Nusa Tenggara, Indonesia

REFERENCES

Adhikari L. 2010. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial *Enterococci*. J. Clob. Infect. Dis. 2, 231–235. https://doi.org/10.4103/0974-777X.68534

Al-dhabi NA., Esmail GA., Ghilan AM, Arasu MV, Duraipandiyan V, Ponmurugan K. 2020. Chemical constituents of *Streptomyce*s sp. strain Al-Dhabi-97 isolated from the marine region of Saudi Arabia with antibacterial and anticancer properties. J. Infect. Public Health 13, 235–243.

Anjum K, Abbas SQ, Shah SAA, Akhter N, Batool S, Hassan SS. 2016. Marine Sponges as a Drug Treasure. Biomol Ther (Seoul) 24(4): 347–362. doi: 10.4062/biomolther.2016.067

Apsari PP, Budiarti SRI, Wahyudi ATRI. 2019. *Actinomycetes* of rhizosphere soil producing antibacterial compounds against urinary tract infection bacteria. Biodiversitas 20, 1259–1265. https://doi.org/10.13057/biodiv/d200504

Asagabaldan MA, Bedoux G, Bourgougnon N. 2019. Bacterial isolates from bryozoan *Pleurocodonellina* sp .: Diversity and antimicrobial potential against pathogenic bacteria. Biodiversitas 20, 2528–2535. https://doi.org/10.13057/biodiv/d200914

Bayraktar B, Pelit S, Bulut ME, Aktas E. 2019. Trend in antibiotic resistance of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* Bloodstream Infections. Sisli Etfal Hastan Tip Bul. 25;53(1):70-75. doi: 10.14744/SEMB.2018.60352.

Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR. 2017. Marine natural products. Nad prod Rep 34, 235–294. https://doi.org/10.1039/c4np00144c

Bologa CG, Ursu O, Oprea T. Melançon CE, Tegos G. 2013. Emerging trends in the discovery of natural product antibacterials cristian. Curr. Opin. Pharmacol. 13, 678–687. https://doi.org/10.1016/j.cortex.2009.08.003.Predictive

CDC. 2019. Biggest Threats and Data 2019 AR Threats Report [WWW Document]. Centers Diesease Control Prev.

Chakraborty K, Thilakan B, Raola VK. 2014. Polyketide family of novel antibacterial 7-O-methyl-5′-hydroxy-3′-heptenoate-macrolactin from seaweed-associated *Bacillus subtilis* MTCC 10403. J. Agric. Food Chem. https://doi.org/10.1021/jf504845m

Cherian T, Yalla S, Mohanraju R. 2019. Antimicrobial potential of methanolic extract of *Bacillus aquimaris* isolated from the marine waters of Burmanallah coast, South Andaman. Int J Biopharm Res 8(12), 2806–2813. https://doi.org/10.21746/ijbpr.2019.8.12.1

Davidson SK, Haygood MG. 1999. Identification of sibling species of the bryozoan *Bugula neritina* that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "*Candidatus Endobugula sertula*". Biol Bull 196, 273–80. https://doi.org/10.2307/1542952

Gonaález AG, Darias V, Estévez E. 1982. Contribution to the biological study of *Spongia officinalis*. Farm. Sci. 37, 179–83.
Jang KH, Chung SC, Shin J, Lee SH, Kim TI, Lee HS, Oh KB. 2007. Aaptamines as sortase A inhibitors from the tropical sponge *Aaptos aaptos*. Bioorganic Med. Chem. Lett. 17, 5366–5369. https://doi.org/10.1016/j.bmcl.2007.08.007
Kim HS, Yoon BD, Lee CH, Suh HH, Oh HM, Katsuragi T, Tani Y. 1997. Production and properties of a lipopeptide biosurfactant from *Bacillus subtilis* C9. J. Ferment. Bioeng. 84, 41–46. https://doi.org/10.1016/S0922-338X(97)82784-5
Kim Y, Pai H, Lee H, Park S, Choi E, Kim-Jungmin. 2002. Bloodstream infections by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in children : epidemiology and clinical outcome. Antimicrob. Agents Chemother. 46, 1481–1491. https://doi.org/10.1128/AAC.46.5.1481
König GM, Kehraus S, Seibert SF, Abdel-lateff A, Müller D. 2006. Natural products from marine organisms and their associated microbes. Chembiochem 7, 229–38. https://doi.org/10.1002/cbic.200500087
Lestari SD, Sadiq ALO, Safitri WA, Dewi SS, Prastiyanto ME. 2019. The antibacterial activities of bacteriocin *Pediococcus acidilactici* of breast milk isolate to against methicillin-resistant *Staphylococcus aureus*. J. Phys. Conf. Ser. 1375, 012021. https://doi.org/10.1088/1742-6596/1374/1/012021
Ma Z, Wang N, Hu J, Wang S. 2012. Isolation and characterization of a new iturinic lipopeptide, mojavensin A produced by a marine-derived bacterium *Bacillus mojavensis* B0621A. J. Antibiot. (Tokyo). 65, 317–322. https://doi.org/10.1038/ja.2012.19
Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. 2010. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31, 255–265. https://doi.org/10.1016/j.tips.2010.02.005
McCaffrey EJ, Endean R. 1985. Antimicrobial activity of tropical and subtropical sponges. Mar. Biol. 89, 1–8.
Mondol MAM, Kim JH, Lee HS, Lee YJ, Shin HJ. 2011. Macrolactin W, a new antibacterial macrolide from a marine *Bacillus* sp. Bioorganic Med. Chem. Lett. 21, 3832–3835. https://doi.org/10.1016/j.bmcl.2010.12.050
Mondol MAM, Shin HJ, Islam MT. 2013. Diversity of secondary metabolites from marine *Bacillus* species: Chemistry and biological activity. Mar. Drugs 11, 2846–2872. https://doi.org/10.3390/md11082846
Nalini S, Richard DS, Riyaz SUM, Kavitha G, Inbakandan D. 2018. Antibacterial macro molecules from marine organisms. Int. J. Biol. Macromol. 115, 696–710. https://doi.org/10.1016/j.ijbiomac.2018.04.110
Nguyen MH, Ito T, Kurimoto S, Ogawa M, Nwet N, Quoc V, Thi H, Kubota T, Morita H. 2017. New merosesquiterpenes from a Vietnamese marine sponge of *Spongia* sp . and their biological activities. Bioorg. Med. Chem. Lett. 27, 3043–3047. https://doi.org/10.1016/j.bmcl.2017.05.060
Odekina PA, Agbo MO, Omeje EO. 2020. Antimicrobial and antioxidant activities of novel marine bacteria (*Bacillus* 2011SOCCUF3) isolated from marine sponge (*Spongia officinalis*). Pharm. Sci. 26, 82–87. https://doi.org/10.34172/PS.2019.59
Prastiyanto ME. 2021. Seeds extract of three *Artocarpus* species : Their in-vitro antibacterial activities against multidrug-resistant (MDR) *Escherichia coli* isolates from urinary tract infections (UTIs). Biodiversitas 22, 4356–4362. https://doi.org/10.13057/biodiv/d221028
Prastiyanto ME, Azizah IH, Haqi HD, Yulianto BD, Agmala AB, Radipasari ZD, Astuti NAD. 2020a. In-vitro antibacterial activity of the seed extract of three member *Artocarpus* towards methicillin resistant *Staphylococcus aureus* (MRSA). J. Teknol. Lab. 9, 1–6. https://doi.org/10.29238/tek
Prastiyanto ME, Rukmana RM, Saraswati DK, Darmawati S, Maharani ETW, Tursinawati Y, 2020b. Anticancer potential of methanolic extracts from *Pleurotus* species on raji cells and antibacterial activity against Methicillin-Resistant *Staphylococcus aureus*. Biodiversitas 21, 5644–5649. https://doi.org/10.13057/biodiv/d211221
Prastiyanto ME, Setyaningtyas A, Trisnawati L, Syafira A. 2016. Antimicrobial activity and identification the compounds of methanol extract from the *Pleurotus ostreatus* fruiting body. El-Hayah: Jurnal Biologi 6, 29-34. https://doi.org/10.18860/elha.v6i1.4082
Prastiyanto ME, Tama PD, Ananda N, Wilson W, Mukaromah AH. 2020c. Antibacterial potential of *Jatropha* sp. latex against Multidrug-Resistant bacteria. Int. J. Microbiol. 2020. https://doi.org/10.1155/2020/8509650
Prastiyanto ME, Wardoyo FA, Wilson W, Darmawati S. 2020d. Antibacterial activity of various extracts of *Averrhoa bilimbi* against multidrug resistant bacteria. Biosaintifika 12, 163–168.
Radjasa OK, Khoeri MM, Darusallam CC, Trimasanto H, Sudoyo H. 2013. Bacterial symbionts of reef invertebrates: Screening for anti-pathogenic bacteria activity. Biodiversity 14, 80–86. https://doi.org/10.1080/14888386.2013.774937
Radjasa OK, Vaske YM, Navarro G, Vervoort HC, Tenney K, Linington RG, Crews P. 2011. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg Med Chem. 19, 6658–6674. https://doi.org/10.1016/j.bmc.2011.07.017.Highlights
Song J, Hsueh P, Chung DR, Ko KS, Kang C, Peck KR. 2011. Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : An ANSORP study Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries : an ANSORP. J Antimicrob Chemother 66, 1062–1069. https://doi.org/10.1093/jac/dkr024

Sun S, Canning CB, Bhargava K, Sun X, Zhu W, Zhou N, Zhang Y, Zhou K. 2015. Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge *Dysidea*. Bioorganic Med. Chem. Lett. 25, 2181–2183. https://doi.org/10.1016/j.bmcl.2015.03.057

Waworuntu O, Sjahril R, Rasita YD, Munawir M. 2021. Characteristic of extended-spectrum-B-lactamase (ESBL) Producing *Klebsiella pneumoniae* at tertiary referral hospital in South Sulawesi, Indonesia. Int. J. Infect. Dis. 101, 80. https://doi.org/10.1016/j.ijid.2020.09.236

Webster NS, Taylor MW. 2012. Marine sponges and their microbial symbionts : love. Environ. Microbiol. 14, 335–346. https://doi.org/10.1111/j.1462-2920.2011.02460.x

Word Health Organization. 2017. Essential medicines and health products Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. (accessed 4.9.21)

Word Health Organization. 2018. Resistance in bacteria Antibiotic. URL http://www.who.int/mediacentre/factsheets/fs194/en/ (accessed 4.9.21).

6 Bukti konfirmasi artikel accepted 09 Februari 2022



7 Bukti konfirmasi artikel published online 09 Feb 20222